

## PUBLICATIONS

**(h Index=84, Number of Citations ~28,000; Wands J, Google Scholar)**

1. *Wands JR*: Electrical properties of liver cells. Medical thesis, University of Washington Press, 1969.
2. *Wands JR, Smuckler EA, Woodbury WJ*: Transmembrane potential changes in liver cells following CC1<sub>4</sub> intoxication. *Am J Pathol* 1970;499-508.
3. *Fisch HP, Wands J, Yeung J, David PJ*: Pulmonary edema and disseminated intravascular coagulation after intravenous abuse of d-propoxyphene. *South Med J* 1972;65:493-5.
4. *Wands JR, Mann RB, Jackson D, Butler T*: Fatal community acquired *Herellea* pneumonia in chronic renal disease. Case Report. *Am Rev Respir Dis* 1973;108:964-7.
5. *Wands JR, Salyer DC, Boitnott JK, Maddrey WB*: Fulminant hepatitis complicated by pancreatitis. *Johns Hopkins Med J* 1973;133:156-60.
6. *Burton JR, Wands JR, Voigt GC, Sterioff S, Caralis DG, Zackary JB, Smith GW*: An approach to pericardial effusion in hemodialysis patients. *Johns Hopkins Med J* 1973;133:312-20.
7. *Wands JR, Carpenter CC, Davis TT*: Hepatitis B in an oncology unit. Morbidity and Mortality 1973;22:294-6.
8. *Mitch WE, Wands JR, Maddrey WC*: Hepatitis B transmission in a family. *JAMA* 1974;227:1043-4.
9. *Wands JR, Weiss SW, Yardley JH, Maddrey WC*: Chronic inorganic mercury poison due to laxative abuse. A clinical and ultrastructural study. *Am J Med* 1974;57:92-101.
10. *James S, Outten W, Davis PJ, Wands JR*: House staff scheduling: a computer-aided method. *Ann Intern Med* 1974;80:70-3.
11. *Davis LE, Wands JR, Weiss SA, Price DL, Girling EF*: Central nervous intoxication from mercurous chloride ingestion. Quantitative, histochemical and ultrastructural studies. *Arch Neurol* 1974;30:428-31.
12. *Levin ME, Maddrey WC, Wands JR, Mendeloff A*: Hepatitis B transmission by dentists. *JAMA* 1974;288:1139-41.
13. *Wands DR, Walker WA, Davis TT, Waterbury LW, Owens AH, Carpenter CCJ*: Hepatitis B in an oncology unit. *N Engl J Med*. 1974;291:1371-5.

14. *Wands JR, Chura CR, Roll FJ, Maddrey WC*: Serial studies of hepatitis associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. *Gastroenterology* 1975;68:105-12.
15. *Wands JR, Perrotto JL, Alpert E, Isselbacher KJ*: Cell-mediated immunity in acute and chronic hepatitis. *J Clin Invest* 1975;55:921-9.
16. *Wands JR, Mann E, Alpert E, Isselbacher KJ*: The pathogenesis of arthritis associated with acute hepatitis-B surface antigen-positive hepatitis: Complement activation and characterization of circulating immune complexes. *J Clin Invest* 1975;55:930-6.
17. *Wands JR, Isselbacher KJ*: Lymphocyte cytotoxicity to autologous liver cells in chronic active hepatitis. *Proc Nat Acad Sci* 1975;72:1301-3.
18. *Wands JR, Alpert E, Isselbacher KJ*: Arthritis associated with chronic active hepatitis: Complement activation and characterization of circulating immune complexes. *Gastroenterology* 1975;69:1286-91.
19. *Wands JR*: Subacute and chronic active hepatitis following withdrawal from chemotherapy. *Lancet* 1975;ii:1120.
20. *Wands JR, Walker JA*: Hepatitis attack rates in an oncology unit. *N Engl J Med* 1975;292:603.
21. *Wands JR, LaMont JT, Mann E, Isselbacher KJ*: Arthritis associated with intestinal bypass procedure for morbid obesity: Complement activation and characterization of circulating cryoproteins. *N Engl J Med* 1976;294:121-4.
22. *Wands JR, Perrotto JL, Isselbacher KJ*: Circulating immune complexes and complement sequence activation in infectious mononucleosis. *Am J Med* 1976;60:269-72.
23. *Wands JR, Rowe JA, Mezey SE, Waterbury LA, Wright JR, Halliday JW, Isselbacher KJ, Powell LW*: Normal serum ferritin concentrations in precirrhotic hemochromatosis. *N Engl J Med* 1976;294:302-5.
24. *Farivar M, Wands JR, Isselbacher KJ, Bucher NL*: Effect of insulin and glucagon in fulminant murine hepatitis. [Letter]. *Lancet* 1976;1:696-7.
25. *Wands JR, Podolsky DK, Isselbacher KJ*: Mechanism of human lymphocyte stimulation by concanavalin A: the role of valence and surface binding sites. *Proc Nat Acad Sci* 1976;73:2118-22.
26. *Farivar M, Wands JR, Benson G, Dienstag JL, Isselbacher KJ*: Cryoprotein complexes and peripheral neuropathy in a patient with chronic active hepatitis. *Gastroenterology* 1976;71:490-3.

27. *Farivar M, Wands JR, Isselbacher KJ, Bucher NL*: Effect of insulin and glucagon on fulminant murine hepatitis. *N Engl J Med* 1976;295:1517-9.
28. *Rowe JR, Wands JR, Mezey E, Waterbury LA, Wright JR, Tobin J, Andreas R*: Familial hemochromatosis: Characteristics of the precirrhotic stage in a large kindred. *Medicine* 1977;56:197-211.
29. *Carter EA, Wands JR, Isselbacher KJ*: Effect of acute murine hepatitis (MHV-1-59) on ethanol oxidation *in vivo*. *Gastroenterology* 1977;73:321-6.
30. *Carter EA, Wands JR, Alpert E, Isselbacher KJ*: Measurement and specificity of serum DNA polymerase. *N Engl J Med* 1977;296:173-4.
31. *Bucher NLR, Wands JR*: Hormone cocktails to stimulate hepatocytes. *N Engl J Med* 1977;296:946.
32. *Feller ER, Pont A, Wands JR, Carter EA, Foster G, Kourides IA, Isselbacher KJ*: Familial hemochromatosis: Physiologic studies in the precirrhotic stage of the disease. *N Engl J Med* 1977;296:1422-26.
33. *Dienstag JL, Wands JR, Isselbacher KJ*: Hepatitis B and essential mixed cryoglobulinemia. *N Engl J Med* 1977;297:946-7.
34. *Wands JR, Dienstag JL, Bhan AK, Feller ER, Isselbacher KJ*: Circulating immune complexes and complement activation in primary biliary cirrhosis. *N Engl J Med* 1978;298:233-7.
35. *Hodgson HJ, Wands JR, Isselbacher KJ*: Alteration in suppressor cell activity in chronic active hepatitis. *Proc Nat Acad Sci* 1978;75:1549-53.
36. *Dienstag JL, Rhodes AR, Bhan AK, Dvorak Am, Mihm MC, Jr., Wands JR*: Urticaria associated with acute viral hepatitis type B: studies of pathogenesis. *Ann Intern Med* 1978;89:34-40.
37. *Dienstag JL, Carter EA, Wands JR, Isselbacher KJ, Fischer JE*: Plasma alpha-amino-n butyric acid to leucine ration: Nonspecificity as a marker for alcoholism. *Gastroenterology* 1978;75:561-5.
38. *Hodgson HJ, Wands JR, Isselbacher KJ*: Decreased suppressor cell activity in inflammatory bowel disease. *Clin Exp Immunol* 1978;32:451-8.
39. *Wands JR, Dienstag JL*: Inhibition of lymphocyte cytotoxicity by serum from patients with alcoholic liver disease: Partial characterization of serum inhibitors. *Yale J Biol Med* 1978;51:615-23.

40. *Quaroni A, Wands JR, Trelstad RL, Isselbacher KJ*: Epithelioid cell cultures from rat small intestine. Characterization by morphologic and immunologic criteria. *J Cell Biol* 1979;80:248-65.
41. *Wands JR, Hodgson HJF*: Suppressor cells in chronic active hepatitis. In: Williams RC, ed. *The International Symposium on Immune Reactivity in Liver Disease*. 1979;118-9.
42. *Wands JR, Carter EA, Bucher NL, Isselbacher KJ*: Inhibition of hepatic regeneration in rats by acute and chronic ethanol intoxication. *Gastroenterology* 1979;77:528-32.
43. *Popp JW, Dienstag JL, Wands JR, Bloch KJ*: Essential mixed cryoglobulinemia without evidence for hepatitis B virus infection. *Ann Intern Med* 1980;92:379-83.
44. *Wands JR, Zurawski VR*: High affinity monoclonal antibodies to hepatitis B surface antigen (HBsAg) produced by somatic cell hybrids. *Gastroenterology* 1981;80:225-32.
45. *Wands JR, Carlson RI, Schoemacher H, Isselbacher KJ, Zurawski VR*: Immunodiagnosis of hepatitis B with high affinity IgM monoclonal antibodies. *Proc Nat Acad Sci* 1981;78:1214-8.
46. *Wands JR, Dienstag JL, Weake JR, Koff RS*. *In vitro* studies of enhanced IgG synthesis in severe alcoholic liver disease. *Clin Exp Immunol* 1981;44:396-404.
47. *Popp JW, Harrist TJ, Dienstag JL, Bhan AK, Wands JR, LaMont JT, Mihm MC*: Cutaneous vasculitis associated with acute and chronic hepatitis. *Arch Int Med* 1981;141:623-9.
48. *Dienstag JL, Weake JR, Wands JR*: Abnormalities in mononuclear cell regulation *in vitro* in primary biliary cirrhosis. *Liver* 1981;1:230-43.
49. *Bhan AK, Dienstag JL, Wands JR, Schlossman SF, Reinherz EL*: Alterations of T-cell subsets in primary biliary cirrhosis. *Clin Exp Immunol* 1982;47:351-8.
50. *Hodgson HJ, Wands JR, Isselbacher KJ*: Experimental murine hepatitis and inducible suppressor cell function. *J Clin Lab Immunol* 1982;7:45-9.
51. *Wands JR, Marciniak RA, Isselbacher KJ, Varghese M, Don G, Halliday JW, Powell LW*: Demonstration of previously undetected hepatitis B viral determinants in an Australian aboriginal population by monoclonal anti-HBs antibody radioimmunoassay. *Lancet* 1982;1:977-80.
52. *Wands JR, Bruns RR, Carlson RI, Ware A, Menitove JE, Isselbacher KJ*: Monoclonal IgM radioimmunoassay for hepatitis B surface antigen: High binding activity in serum that is unreactive with conventional antibodies. *Proc Nat Acad Sci* 1982;79:1277-81.

53. *Shouval D, Wands JR, Zurawski VR, Isselbacher KJ, Shafritz DA*: Selecting binding and complement mediated lysis of human hepatoma cells (PLC/PRF/5) in culture by monoclonal antibodies to hepatitis B surface antigen. *Proc Nat Acad Sci* 1982;79:650-54.
54. *Shouval D, Shafritz DA, Zurawski VR, Jr., Isselbacher KJ, Wands JR*: Immunotherapy in nude mice of human hepatoma using monoclonal antibodies against hepatitis B virus. *Nature* 1982;298:567-9.
55. *Shouval D, Wands JR, Zurawski VR, Jr., Isselbacher KJ, Shafritz DA*: Protection against experimental hepatoma formation in nude mice by monoclonal antibodies to hepatitis B virus surface antigen. *Hepatology* 1982;2:128S-33S.
56. *Goodson JD, Taylor PA, Campion EW, Richter JM, Wands JR*: The clinical course of acute hepatitis in the elderly. *Arch Intern Med* 1982;142:1485-8.
57. *Shafritz DA, Lieberman HM, Isselbacher KJ, Wands JR*: Monoclonal radioimmunoassays for hepatitis B surface antigen: Demonstration of hepatitis B virus DNA or related sequences in serum and viral epitopes in immune complexes. *Proc Nat Acad Sci* 1982;79:5675-9.
58. *Wands JR, Lieberman H, Muchmore E, Isselbacher KJ, Shafritz DA*: Detection and transmission in chimpanzees of hepatitis B virus-related agents formerly designated “non-A, non-B” hepatitis. *Proc Nat Acad Sci* 1982;79:7552-6.
59. *Marciniak R, Wands JR, Bruns RR, Malchesky PS, Nose Y, Haber E*: Quantitative removal of hepatitis B viral antigens from serum by a monoclonal IgM coupled to a biocompatible solid phase support. *Proc Nat Acad Sci* 1983;80:3821-25.
60. *Bellet DH, Wands JR, Isselbacher KJ, Bohoun C*: Serum alpha-fetoprotein levels in human disease: perspective from a highly specific monoclonal radioimmunoassay. *Proc Nat Acad Sci* 1984;81:3869-73.
61. *Ben-Porath E, Wands JR, Gruia M, Isselbacher KJ*: Clinical significance of enhanced detection of HBsAg by a monoclonal radioimmunoassay. *Hepatology* 1984;4:803-7.
62. *Wands JR, Wong AM, Shorey J, Brown RD, Marciniak RA, Isselbacher KJ*: Hepatitis B viral antigenic structure: signature analysis by monoclonal radioimmunoassays. *Proc Nat Acad Sci*. 1984;81:2237-41.
63. *He L, Isselbacher KJ, Wands JR, Goodman HM, Shih C, Quaroni A*: Establishment and characterization of a new human hepatocellular carcinoma cell line. *In Vitro* 1984;20:493-504.
64. *Cooper DA, Carter EA, Kieffer JD, Wands JR*: Effects of propylthiouracil on D-galactosamine hepatotoxicity in the rat. Evidence for a non-thyroidal effect. *Biochem Pharmacol* 1984;33:3391-7.

65. *Brechot C, Degos F, Lugassy C, Thiers V, Zafrani S, Franco D, Bismuth H, Trepo C, Benhamou JP, Wands J, Isselbacher KJ, Tiollais P, Berthelot P:* Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. *N Engl J Med* 1985;312:270-6.
66. *Bidart JM, Ozturk M, Bellet DH, Jolivet M, Gras-Masse H, Troalen F, Bohuon C, Wands JR:* Identification of epitopes associated with hCG and beta hCG carboxyl terminus by monoclonal antibodies produced against a synthetic peptide. *J Immunol* 1985;134:457-64.
67. *Ben-Porath E, Wands JR, Bar-Shany S, Huggins C, Isselbacher KJ:* Improved detection of hepatitis B surface antigen (HBsAg) in blood donors by monoclonal radioimmunoassay. *Transfusion* 1985;25:10-4.
68. *Wands JR, Isselbacher KJ, Brechot C, Tiollais P:* Monoclonal radioimmunoassays and HBV-DNA hybridization in hepatocellular carcinoma [letter]. *Lancet* 1985;a:455
69. *Carter EA, Wands JR:* Ethanol inhibits hormone stimulated hepatocyte DNA synthesis. *Biochem Biophys Res Commun* 1985;128:767-74.
70. *Shouval D, Eilat D, Carlson RI, Adler R, Livni N, Wands JR:* Human hepatoma associated cell surface antigen: Identification and characterization by means of monoclonal antibodies. *Hepatology* 1985;5:347-56.
71. *Carlson RI, Ben-Porath E, Shouval D, Strauss W, Isselbacher KJ, Wands JR:* Antigenic characterization of human hepatocellular carcinoma: Development of *in vitro* and *in vivo* immunoassays that use monoclonal antibodies. *J Clin Invest* 1985;76:40-51.
72. *Ben-Porath E, Wands JR, Marciniak RA, Wong MA, Hornstein L, Ryder R, Canlas M, Lingao A, Isselbacher KJ:* Structural analysis of hepatitis B surface antigen by monoclonal antibodies. *J Clin Invest* 1985;76:1338-47.
73. *Gazitt Y, Margel S, Lerner A, Wands JR, Shouval D:* Development of a novel C1q immunoadsorbent for removal of circulating immune complexes: Quantitative isolation of hepatitis B virus surface antigen and immune complexes. *Immunol Lett* 1985;11:1-8.
74. *Gross J, Carlson RI, Brauer AW, Margolies MN, Warshaw AL, Wands JR:* Isolation, characterization and distribution of an unusual pancreatic human secretory protein. *J Clin Invest* 1985;76:2115-26.
75. *Monath TP, Hill LJ, Brown NV, Cropp CB, Schlesinger JJ, Saluzzo JF, Wands JR:* Sensitive and specific monoclonal immunoassay for detecting yellow fever virus in laboratory and clinical specimens. *J Clin Microbiol* 1986;23:129-34.

76. *Monath TP, Wands JR, Hill LJ, Gentry MK, Gubler DB*: Multisite monoclonal immunoassays for Dengue viruses: Detection of viremic human sera and interference by heterologous antibody. *J Gen Viol* 1986;67:639-50.
77. *Ratner AV, Carter EA, Pohost GM, Wands JR*: Nuclear magnetic resonance spectroscopy and imaging in the study of experimental liver disease. *Alcoholism: J Clin Exp Res* 1986;10:241-5.
78. *Wands JR, Fujita YK, Isselbacher KJ, Degott C, Schellekens H, Dazza MC, Thiers V, Tiollais P, Brechot C*: Detection and transmission of hepatitis B virus related variants. *Proc Natl Acad Sci (USA)* 1986;83:6608-12.
79. *Kew MC, Fujita Y, Takahashi H, Coppins A, Wands JR*: Comparison between polyclonal and first and second generation monoclonal radioimmunoassays in the detection of hepatitis B surface antigen in patients with hepatocellular carcinoma. *Hepatology* 1986;6:636-39.
80. *Fujita YK, Kamata K, Kameda H, Isselbacher KJ, Wands JR*: Detection of hepatitis B virus infection in hepatitis B surface antigen-negative hemodialysis patients by monoclonal radioimmunoassays. *Gastroenterology* 1986;91:1357-63.
81. *Shouval D, Adler A, Wands JR, Hurwitz E*: Conjugates between monoclonal antibodies to HBsAg and cytosine arabinoside. *J Hepatol* 1986;3:S87-95.
82. *Zeldis JB, Ben-Porath E, Enat R, Kirsch K, Wands JR*: Correlation of HBV-DNA and monoclonal reactivity to HBsAg in serum of patients with HBV infection. *J Virol Methods* 1986;14:153-66.
83. *Monath TP, Wands JR, Hill LJ, Brown NV, Marciniak RA, Wong MA, Gentry MK, Burk DS, Grant JA, Trient DW*: Geographic classification of dengue-2 virus strains by antigen signature analysis. *Virology* 1986;154:313-24.
84. *Bellet DH, Ozturk M, Bidart JM, Bohuon CJ, Wands JR*: Sensitive and specific assay for human chorionic gonadotropin (hCG) based on anti-peptide and anti-hCG monoclonal antibodies: construction and clinical implications. *J Clin Endocrinol Metab* 1986;63:1319-27.
85. *Shouval D, Wands JR, Shafritz DA*: Immunotherapy of human hepatocellular carcinoma: molecular and cellular studies with monoclonal antibodies to hepatitis B viral determinants. *Intracellular Intracell Commun* 1986;2:221-38.
86. *Ozturk M, Bellet D, Manil L, Hennen G, Frydman R, Wands JR*: Physiological studies of human chorionic gonadotropin (hCG), alpha hCG and beta hCG as measured by specific monoclonal immunoradiometric assays. *Endocrinology* 1987;120:549-58.

87. *Ozturk M, Bellet D, Isselbacher KJ, Wands JR*: Ectopic beta-human chorionic gonadotropin production by a human hepatoma cell line (FOCUS): isolation and immunochemical characterization. *Endocrinology* 1987;120:559-66.
88. *Shih C, Burke K, Chou MJ, Zeldis JB, Yang CS, Lee CS, Isselbacher KJ, Wands JR, Goodman HM*. Tight clustering of human hepatitis B virus integration sites in hepatomas near a triple-stranded region. *J Virol* 1987;61:3491-8.
89. *Bellet DH, Bidart JM, Ozturk M, Troalen F, Ghillani P, Pernas P, Wands JR, Bohuon C*: Synthetic peptides and monoclonal antibodies of predetermined specificity in the study of human chorionic gonadotropin. *Int J Rad Appl Instrum B* 1987;14:295-304.
90. *Pol S, Thiers V, Nalpas B, Degos F, Gazengel C, Carnot F, Tiollais P, Wands JR, Berthelot P, Brechot C*: Monoclonal anti-HBs radioimmunoassay and serum HBV-DNA hybridization as diagnostic tools of HBV infection: relative prevalence among HBsAg negative alcoholics, patients with chronic hepatitis or hepatocellular carcinomas and blood donors. *Eur J Clin Invest* 1987;17:515-521.
91. *Ozturk M, Berkowitz R, Goldstein D, Bellet D, Wands JR*: Differential production of human chorionic gonadotropin and free subunits in gestational trophoblastic disease. *Am J Obstet Gynecol* 1988;158:193-8.
92. *Wilson B, Ozturk M, Takahashi H, Motte P, Kew M, Isselbacher KJ, Wands JR*: Cell surface changes associated with transformation of human hepatocytes to the malignant phenotype. *Proc Natl Acad Sci USA* 1988;85:3140-4.
93. *Carter EA, Wands JR*: Ethanol induced inhibition of liver cell function. I. Effect of ethanol on hormone stimulated hepatocyte DNA synthesis and the role of ethanol metabolism. *Alcohol Clin Exp Res* 1988;12:555-62.
94. *Takahashi H, Kameda H, Wands JR*: Development of a second generation monoclonal immunoradiometric assay. Increased sensitivity leads to enhanced detection of hepatitis B viral infection. *J Immunol Methods* 1988;112:191-200.
95. *Shouval D, Adler R, Wands JR, Hurwitz E, Isselbacher KJ, Sela M*: Doxorubicin conjugates of monoclonal antibodies to hepatoma associated proteins. *Proc Natl Acad Sci USA* 1988;85:8276-80.
96. *Takahashi H, Wilson B, Ozturk M, Motte P, Strauss W, Isselbacher KJ, Wands JR*: *In vivo* localization of colon adenocarcinoma by monoclonal antibody binding to a highly expressed cell surface antigen. *Cancer Res* 1988;48:6573-9.
97. *Thiers V, Nakajima E, Kremsdorf D, Schellekens H, Driss F, Goudeau A, Wands JR, Sninsky J, Tiollais P, Ozawa K, Brechot C*: Transmission of hepatitis B from hepatitis-B-seronegative subjects. *Lancet* 1988;2:1273-6.



98. *Ozturk M, Brown H, Milunsky A, Wands JR*: Physiological studies of human chorionic gonadotropin and free subunits in the amniotic fluid compartment compared to those in maternal serum. *J Clin Endocrinol Metab* 1988;67:1117-21.
99. *Milunsky A, Wands JR, Brambati B, Bonnachi I, Currie K*: First trimester maternal serum alpha fetoprotein screening for chromosome defects. *Am J Obstet Gynecol* 1988;159:1209-13.
100. *Poynard T, Marcellin P, Wands JR, Naveau S, Durbreuil P, Pillot J, Chaput JC*. Detection of hepatitis B surface antigen (HBsAg) in a monoclonal radioimmunoassay (M-RIA) in the serum of alcoholic patients revealed a high prevalence of HBV infection in patients with cirrhosis. *J Gastroenterol Hepatol* 1988;3:153-8.
101. *Motte P, Takahashi H, Ozturk M, Wilson BE, Wands JR*. Characterization of a malignant phenotype-associated cell surface glycoprotein common to various human tumor cells and preferentially expressed on adenocarcinoma of the lung. *Cancer Res* 1989;49:1349-56.
102. *Ozturk M, de la Monte S, Gross J, Wands JR*. Elevated levels of an exocrine pancreatic secretory protein in Alzheimer's disease brain. *Proc Natl Acad Sci USA*. 1989;86:419-23.
103. *Takahashi H, Ozturk M, Wilson B, Maki A, Ozawa K, Koizumi M, Endo K, Strauss W, Shouval W, Wands JR*. *In vivo* expression of two novel tumor associated antigens and their use in immunolocalization of human hepatocellular carcinoma. *Hepatology* 1989;9:625-34.
104. *Takahashi H, Carlson R, Ozturk M, Sun S, Motte P, Strauss W, Isselbacher KJ, Wands JR, Shouval D*: Radioimmunolocalization of hepatic and pulmonary metastasis of human colon adenocarcinoma. *Gastroenterology* 1989;96:1317-29.
105. *Berkowitz R, Ozturk M, Goldstein D, Bernstein M, Hill L, Wands JR*. Human chorionic gonadotropin and free subunits serum levels in patients with partial and complete hydatidiform moles. *Obstet Gynecol* 1989;74:212-6.
106. *Ozturk M, Motte P, Takahashi H, Frohlich M, Wilson B, Hill L, Bressac B, Cummings W, Wands JR*. Identification and characterization of a Mr 50,000 adrenal protein in human hepatocellular carcinoma. *Cancer Res* 1989;49:6764-73.
107. *Liang TJ, Isselbacher KJ, Wands JR*. Rapid identification of low level hepatitis B or related viral genome in serum. *J Clin Invest* 1989;84:1367-71.
108. *Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M*. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. *Proc Natl Acad Sci USA* 1990;87:1973-7.

109. *Nishiyama M, Ozturk M, Frohlich M, Mafune K, Steele G Jr, Wands JR.* Expression of human alpha-actinin in human hepatocellular carcinoma. *Cancer Res* 1990;50:6291-4.
110. *de la Monte SM, Ozturk M, Wands JR.* Enhanced expression of an exocrine pancreatic protein in Alzheimer's disease and the developing human brain. *J Clin Invest* 1990;86:1004-13.
111. *Ozturk M, Milunsky A, Brambati B, Sachs ES, Miller S, Wands JR.* Abnormal maternal serum levels of human chorionic gonadotropin free subunits in Trisomy 18. *Am J Human Genet* 1990;36:480-3.
112. *Paterlini P, Gerken G, Nakajima F, Terre S, D'Errico A, Grigioni W, Nalpas B, Franco D, Wands JR, Kew M, Pisi E, Tiollais P, Brechot C.* Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen [see comments]. *N Engl J Med* 1990;323:80-5.
113. *Liang TJ, Blum HE, Wands JR.* Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers. *Hepatology* 1990;12:204-12.
114. *Nebiolo L, Ozturk M, Brambati B, Miller S, Wands JR, Milunsky A.* First trimester maternal serum alpha-fetoprotein and human chorionic gonadotropin screening for chromosome defects. *Prenat Diagn* 1990;10:575-581.
115. *Hurwitz E, Stancovski I, Wilchek M, Shouval D, Takahashi H, Wands JR, Sela M.* A conjugate of 5-fluorouridine-poly (L-lysine) and an antibody reactive with human colon carcinoma. *Bioconjug Chem* 1990;1:285-90.
116. *Frohlich M, Motte P, Galvin K, Takahashi H, Wands JR, Ozturk M.* Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma. *Mol Cell Biol* 1990;10:3216-23.
117. *Blum HE, Galun E, Liang TJ, vonWeizsaecker F, Wands JR.* Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication. *J Virol* 1991;65:1836-42.
118. *Bressac B, Kew M, Wands J, Ozturk M.* Selective G to T mutations of p53 gene in hepatocellular carcinoma from Southern Africa. *Nature* 1991;350:429-31.
119. *Blum HE, Galun E, vonWeizsaecker F, Wands JR.* Inhibition of hepatitis B virus by antisense oligodeoxynucleotides. *Lancet* 1991;337:1230.
120. *Wilson BE, Sun S, Ozturk M, Wands JR.* Stability of monoclonal antibody defined epitopes. *J Immunol Methods* 1991;139:55-64.

121. *Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E.* A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. *N Engl J Med* 1991;324:1705-9.
122. *Marcellin P, Calmus Y, Takahashi H, Zigueo AL, Chatenoud L, Galanaud LP, Bach LF, Benhamou JP, Tiollais P, Wands JR, Brechot C.* Latent hepatitis B virus (HBV) infection in systemic necrotizing vasculitis. *Clin Exp Rheumatol* 1991;9:23-8.
123. *Liang TJ, Baruch Y, Ben-Porath E, Enat R, Bassan L, Brown NV, Rimon N, Blum HE, Wands JR.* Hepatitis B virus infection in patients with idiopathic liver disease. *Hepatology* 1991;13:1044-51.
124. *Blum HE, Liang TJ, Galun E, Wands JR.* Persistence of hepatitis B viral DNA after serological recovery from hepatitis B virus infection. *Hepatology* 1991;14:56-63.
125. *Wands JR, Blum HE.* Primary hepatocellular carcinoma. *N Engl J Med* 1991;325:729-31.
126. *Hasegawa K, Huang JK, Wands JR, Obata H, Liang TJ.* Association of hepatitis B viral precore mutations with fulminant hepatitis B in Japan. *Virology* 1991;185:460-3.
127. *Wands JR, Blum H.* Hepatitis B and C virus and alcohol-induced liver injury. *Hepatology* 1991;14:730-3.
128. *Ozturk M, Bressac B, Puisieux A, Kew M, Volkmann M, Bozcali S, Bella Mura J, de la Monte S, Blum HE, Wands JR, Takahashi H, vonWeizsaecker F, Galun E, Schroder CH, Liang XH, Tang Z, Rustgi VK, Prate J, Toda G, Koch H, Erken E, Varinli S, Shouval D, Vyas GN, Sarosi I.* A p53 gene mutational hotspot in primary liver cancer is geographically confined to high aflatoxin areas in the world. *Lancet* 1991;338:1356-9.
129. *Takahashi H, Puisieux I, Nakada T, Wands JR.* Two chimeric monoclonal antibodies with identical IgG<sub>1</sub> human 1c domain exhibit different antitumor effects on human colon cancer *in vivo*. *Antibody Immunoconjugates Radiopharmaceuticals* 1991;41:208.
130. *Blum HE, Zhang ZS, Galun E, von Weizsacker F, Garner B, Liang TJ, Wands JR:* Hepatitis B virus X protein is not central to the viral life cycle *in vitro*. *J Virol* 1992;66:1223-7.
131. *Galun E, Offensperger WB, von Weizsaecker F, Offensperger S, Wands JR, Blum HE.* Human non-hepatocytes support hepadnaviral replication and virion production. *J Gen Virol* 1992;73:173-8.
132. *Nishiyama M, Wands JR.* Cloning and increased expression of an insulin receptor substrate-1 like gene in human hepatocellular carcinoma. *Biochem Biophys Res Commun* 1992;183:280-5.
133. *Marcillac I, Troalen F, Bidard JM, Ghillani P, Ribrag V, Escudier B, Malassagne B, Droz JP, Lhomme C, Rougier P, Duvillard P, Prade M, Lugagne PM, Richard F,*

- Poynard T, Bohuon C, Wands JR, Bellet D.* Detection of free human chorionic gonadotropin beta subunit and nongonadal neoplasms. *Cancer Res* 1992;52:3901-7.
134. *Galvin K, Krishna S, Ponchel F, Frohlich M, Cummings DE, Carlson R, Wands JR, Isselbacher KJ, Pillai S, Ozturk M.* The MHC class I antigen-binding protein p88 is the product of the calnexin gene. *Proc Natl Acad Sci USA* 1992;89:8452-6.
  135. *de la Monte SM, Wands JR:* Neuronal thread protein over-expression in brains with Alzheimer's disease lesions. *J Neurol Sci* 1992;113:152-64.
  136. *de la Monte SM, Volicer L, Hauser S, Wands JR.* Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimers disease. *Ann Neurol* 1992;32:733-42.
  137. *de la Monte SM, Spratt RA, Chong J, Ghanbari HA, Wands JR.* Immunohistochemical and histopathologic correlates of Alzheimer's disease-associated Alz-50 immunoreactivity quantified in homogenates of cerebral tissue. *Am J Pathol* 1992;141:1459-69.
  138. *Chong JK, Cantrell L, Husain M, Riesing S, Miller BE, Wands JR, de la Monte S, Ghanbari HA.* Automated microparticle enzyme immunoassay for neural thread protein in cerebrospinal fluid from Alzheimer's disease patients. *J Clin Lab Anal* 1992;6:379-83.
  139. *McLaughlin JP, Looney JE, Takahashi H, Wands JR, Zurawski VR Jr., Nedelman MA, Woo DV.* Localization and tumoricidal effects of chimeric SF25 monoclonal antibody in human colon carcinoma xenografts. *Proc Ann Meet Am Assoc Cancer Res* 1992;33:A3305.
  140. *Hurwitz E, Adler R, Shouval D, Takahashi H, Wands JR, Sela M.* Immunotargeting of daunomycin to localized and metastatic human colon adenocarcinoma in athymic mice. *Cancer Immunol Immunother* 1992;35:186-92.
  141. *von Weizsaecker F, Blum HE, Wands JR.* Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template. *Biochem Biophys Res Commun* 1992;189:743-8.
  142. *Sasaki Y, Zhang XF, Nishiyama M, Avruch J, Wands JR.* Expression and phosphorylation of insulin receptor substrate 1 during rat liver regeneration. *J Biol Chem* 1993;268:3805-8.
  143. *Liang TJ, Makdisi WJ, Sun S, Hasegawa K, Zhang Y, Wands JR, Wu CH, Wu GY.* Targeted transfection and expression of hepatitis B viral DNA in human hepatoma cells. *J Clin Invest* 1993;91:1241-6.

144. *Haruta I, Wands JR, de la Monte S.* Impaired insulin-mediated up-regulation of glyceraldehyde-3-phosphate dehydrogenase gene expression by acute ethanol exposure *in vitro*. *Internat Hepatol Commun* 1993;1:260-6.
145. *Xu YY, Wands JR, de la Monte SM.* Characterization of thread proteins expressed in neuroectodermal tumors. *Cancer Res* 1993;53:3823-9.
146. *Bhavani K, Brown NV, Carlson RI, Rhoads D, Wands JR:* The effect of ethanol and extracellular matrix on induction of p36 protein kinase substrate expression in rat hepatocytes. *Biochem Biophys Res Commun* 1993;196:1454-8.
147. *Moradpour D, Wands JR, Melegari M.* Chasing the escape mutant. *Hepatology* 1993;18:1011-4.
148. *Melegari M, Bruno S, Wands JR.* Properties of hepatitis B virus pre-S1 deletion mutants. *Virology* 1994;199:292-300.
149. *Sasaki Y, Wands JR.* Ethanol impairs insulin receptor substrate-1 mediated signal transduction during rat liver regeneration. *Biochem Biophys Res Commun* 1994;199:403-9.
150. *Nishiyama M, Inazawa J, Ariyama T, Nakamura Y, Matsufuji S, Furusaka A, Tanaka T, Hayashi S, Wands JR.* The human insulin receptor substrate-1 gene (IRS-1) is localized on 2q36. *Genomics* 1994;20:139-41.
151. *Wakita T, Wands JR.* Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. *J Biol Chem* 1994;269:14205-10.
152. *vonWeizsacker F, Blum HE, Wands JR.* PCR analysis of hepatitis B virus DNA in formalin-fixed, paraffin-embedded liver biopsies from alcoholics using a simplified and standardized amplification protocol. *J Hepatol* 1994;20:646-9.
153. *Liang TJ, Bodenheimer HC Jr, Yankee R, Brown NV, Chang K, Huang J, Wands JR.* Presence of hepatitis B and C viral genomes in US blood donors as detected by polymerase chain reaction amplification. *J Med Virol* 1994;42:151-7.
154. *de la Monte SM, Wands JR.* Diagnostic utility of quantitating neurofilament immunoreactive Alzheimer's disease lesions. *J Histochem Cytochem* 1994;42:1625-34.
155. *Scaglioni PP, Melegari M, Wands JR.* Characterization of hepatitis B virus core mutants that inhibit viral replication. *Virology* 1994;205:112-20.
156. *Sasaki Y, Hayashi N, Ito T, Fusamoto H, Kamada T, Wands JR.* Influences of ethanol on insulin receptor substrate-1-mediated signal transduction during rat liver regeneration. *Alcohol Alcohol* 1994 29:99-106.

157. *Ackerman Z, Wands JR, Gazitt Y, Brechot C, Kew MC, Shouval D.* Enhancement of HBsAg detection in serum of patients with chronic liver disease following removal of circulating immune complexes. *J Hepatol* 1994;20:398-404.
158. *Takahashi H, Nakada T, Nakaki M, Wands JR.* Inhibition of hepatic metastases of human colon cancer in nude mice by chimeric SF-25 monoclonal antibody. *Gastroenterology* 1995;108:172-82.
159. *Bhavani K, de la Monte S, Brown NV, Xu YY, Sasaki Y, Wands JR:* Effect of ethanol on p36 protein kinase substrate and insulin receptor substrate 1 expression and tyrosyl phosphorylation in human hepatocellular carcinoma cells. *Alcohol Clin Exp Res* 1995;19:441-6.
160. *Moradpour D, Wands JR.* Understanding hepatitis B virus infection. *N Engl J Med* 1995;332:1092-3.
161. *de la Monte SM, Bhavani K, Xu YY, Puisieux A, Wands JR.* Modulation of p36 gene expression in human neuronal cells. *J Neurol Sci* 1995;128:122-33.
162. *Maia M, Takahashi H, Adler K, Garlick RK, Wands JR.* Development of a two-site immuno-PCR assay for hepatitis B surface antigen. *J Virol Methods* 1995;52:273-86.
163. *Iwata K, Wakita T, Okumura A, Yoshioka K, Takayanagi M, Wands JR, Kakumu A.* Interferon gamma production by peripheral blood lymphocytes to hepatitis C virus core protein in chronic hepatitis C infection. *Hepatology* 1995;22:1057-64.
164. *Adler R, Hurwitz E, Wands JR, Sela M, Shouval D.* Specific targeting of adriamycin conjugates with monoclonal antibodies to hepatoma associated antigens to intrahepatic tumors in athymic mice. *Hepatology* 1995;22:1482-7.
165. *vonWeizsacker F, Maeda E, Brown NV, Poynard T, Galun E, Labeit S, Caput J-C, Arima T, Blum H, Wands JR.* Hepatitis B and C virus infection in HBsAg-negative alcoholics without i.v. drug abuse or previous blood transfusions. *International Hepatol Commun* 1995;4:80-7.
166. *Xu YY, Bhavani K, Wands JR, de la Monte SM.* Insulin-induced differentiation and modulation of neuronal thread protein expression in primitive neuroectodermal tumor cells is linked to phosphorylation of the insulin receptor substrate-1. *J Mol Neurosci* 1995;6:91-108.
167. *Moradpour D, Compagnon B, Wilson BE, Nicolau C, Wands JR.* Specific targeting of human hepatocellular carcinoma cells by immunoliposomes *in vitro*. *Hepatology* 1995;22:1527-37.

168. *Xu YY, Bhavani K, Wands JR, de la Monte SM.* Ethanol inhibits insulin receptor substrate-1 tyrosine phosphorylation and insulin-stimulated neuronal thread protein gene expression. *Biochem J* 1995;310:125-32.
169. *Tong S, Li J, Wands JR.* Interaction between duck hepatitis B virus and a 170 kilodalton cellular protein is mediated through a neutralizing epitope of the pre-S region and occurs during viral infection. *J Virol* 1995;69:7106-12.
170. *Moradpour D, Wakita T, Tokushige K, Carlson RI, Krawczynski K, Wands JR.* Characterization of three novel monoclonal antibodies against hepatitis C virus core protein. *J Med Virol* 1996;48:234-41.
171. *Ito T, Sasaki Y, Wands JR:* Overexpression of human insulin receptor substrate 1 induces cellular transformation with activation of mitogen-activated protein kinases. *Mol Cell Biol* 1996;16:943-51.
172. *Yoshikawa H, de la Monte S, Nagai H, Wands JR, Matsubara K, Fujiyama A:* Chromosomal assignment of human genomic NotI restriction fragments in a two-dimensional electrophoresis profile. *Genomics* 1996;31:28-35.
173. *Moradpour D, Schauer JJ, Zurawski VR, Wands JR, Boutin RH.* Efficient gene transfer into mammalian cells with cholesteryl-spermidine. *Biochem Biophys Res Commun* 1996;221:82-8.
174. *de la Monte S, Xu YY, Hutchins GM, Wands JR.* Developmental patterns of neuronal thread protein gene expression in Down syndrome. *J Neurol Sci* 1996;135:118-25.
175. *Tanaka S, Ito T, Wands JR:* Neoplastic transformation induced by insulin receptor substrate-1 overexpression requires an interaction with both Grb2 and Syp signaling molecules. *J Biol Chem* 1996;271:14610-6.
176. *Tokushige K, Wakita T, Pachuk C, Moradpour D, Weiner D, Zurawski V, Wands JR.* Expression and immune response to HCV core DNA based vaccine constructs. *Hepatology* 1996;24:14-20
177. *de la Monte SM, Xu YY, Wands JR:* Modulation of neuronal thread protein expression with neuritic sprouting: relevance to Alzheimer's disease. *J Neurol Sci* 1996;138:26-35.
178. *Heller R, Jaroszeski M, Atkin A, Moradpour D, Gilbert R, Wands JR, Nicolau C.* *In vivo* gene electroinjection and expression in rat liver. *FEBS Lett* 1996;389:225-8.
179. *Li JS, Tong SP, Wands JR.* Characterization of a 120-Kilodalton pre-S binding protein as a candidate duck hepatitis B virus receptor. *J Virol* 1996;70:6029-35.

180. *Tanaka S, Wands JR.* Insulin receptor substrate-1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor  $\beta$ 1-induced apoptosis. *Cancer Res* 1996;56:3391-4.
181. *Moradpour D, Englert C, Wakita T, Wands JR.* Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. *Virology* 1996;222:51-63.
182. *Lavaissiere L, Jia S, Nishiyama M, de la Monte S, Stern AM, Wands JR, Friedman PA.* Overexpression of human aspartyl (asparaginyl)  $\beta$  hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. *J Clin Invest* 1996;98:1313-23.
183. *de la Monte SM, Carlson RI, Brown NV, Wands JR.* Profiles of neuronal thread protein expression in Alzheimer's disease. *J Neuropathol Exp Neurol* 1996;55:1038-50.
184. *Scaglioni P, Melegari M, Takahashi M, Chowdhury JR, Wands JR.* Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. *Hepatology* 1996;24:1010-7.
185. *Tanaka S, Wands JR.* A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. *J Clin Invest* 1996;98:2100-8.
186. *Scaglioni PP, Melegari M, Wands JR.* Posttranscriptional regulation of hepatitis B virus replication by the precore protein. *J Virol* 1997;71:345-53.
187. *Geissler M, Gesien A, Tokushige K, Wands JR.* Enhancement of cellular and humoral immune responses to hepatitis C virus core proteins using DNA based vaccines augmented with cytokine expressing plasmids. *J Immunol* 1997;158:1231-7.
188. *Tokushige K, Moradpour D, Wakita T, Geissler M, Hayashi N, Wands JR.* Comparison between cytomegalovirus promoter and elongation factor 1  $\alpha$ -promoter driven constructs in the establishment of cell lines expressing hepatitis C virus core protein. *J Virol Methods* 1997;64:73-80.
189. *Tanaka S, Mori M, Akiyoshi T, Mafune K, Wands JR, Sugimachi K.* Co-expression of Grb7 with epidermal growth factor receptor or Her2/erbB2 in human advanced esophageal carcinoma. *Cancer Res* 1997;57:28-31.
190. *Geissler M, Tokushige K, Chante CC, Zurawski VR, Wands JR.* Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA-based immunization. *Gastroenterology* 1997;112:1307-20.
191. *Compagnon B, Moradpour D, Alford DR, Larsen CE, Stevenson MJ, Mohr L, Wands JR, Nicolau C.* Enhanced gene delivery and expression in human hepatocellular carcinoma cells by cationic immunoliposomes. *J Liposome Res* 1997;7910:127-41.



192. *Melegari M, Scaglioni PP, Wands JR.* The small envelope protein is required for secretion of a naturally occurring hepatitis B virus mutant with pre-S1 deleted. *J Virol* 1997;71:5449-54.
193. *Geissler M, Wands G, Gesien A, de la Monte SM, Bellet D, Wands JR.* Genetic immunization with the free human chorionic gonadotropin  $\beta$  subunit elicits cytotoxic T lymphocyte responses and protects against tumor formation in mice. *Lab Invest* 1997;76:859-71.
194. *Scaglioni PP, Melegari M, Wands JR.* Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. *Virology* 1997;233:374-81.
195. *de la Monte SM, Garner W, Wands JR.* Neuronal thread protein gene modulation with cerebral infarction. *J Cereb Blood Flow Metab* 1997;17:623-35.
196. *Tanaka S, Mohr L, Schmidt EV, Sugimachi K, Wands JR.* Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. *Hepatology* 1997;26:598-604.
197. *Geissler M, Gesien A, Wands JR.* Chronic ethanol effects on cellular immune responses to hepatitis B virus envelope protein: an immunologic mechanism for induction of persistent viral infection in alcoholics. *Hepatology* 1997;26:764-77.
198. *Wands JR, Lavaissiere L, Moradpour D, de la Monte SM, Mohr L, Nicolau C, Tanaka S:* Immunological approach to hepatocellular carcinoma. *J Viral Hepat* 1997;4:60-74.
199. *de la Monte SM, Sohn YK, Wands JR.* Correlates of p53- and Fas(CD95)-mediated apoptosis in Alzheimer's disease. *J Neurol Sci* 1997;152:73-83.
200. *Geissler M, Gesien A, Wands JR.* Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core protein are reversed by genetic immunizations augmented with cytokine-expressing plasmids. *J Immunol* 1997;159:5107-13.
201. *de la Monte S, Ghanbari K, Frey WH, Beheshti I, Averback P, Hauser SL, Ghanbari HA, Wands JR.* Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid. *J Clin Invest* 1997;100:3093-104.
202. *Wands JR, Geissler M, zu Putlitz J, Blum H, vonWeizsacker F, Mohr L, Yoon SK, Melegari M, Scaglioni PP.* Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection. *J Gastroenterol Hepatol* 1997;12:S354-69.
203. *Melegari M, Scaglioni PP, Wands JR.* Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. *Hepatology* 1998;27:628-33.

204. *Melegari M, Scaglioni PP, Wands JR.* Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication. *J Virol* 1998;72:1737-43.
205. *de la Monte SM, Sohn YK, Ganju N, Wands JR.* p53- and CD95 associated apoptosis in neurodegenerative diseases. *Lab Invest* 1998;78:401-11.
206. *Geissler M, Schirmbeck R, Reimann J, Blum HE, Wands JR.* Cytokine and hepatitis B virus DNA co-immunizations enhance cellular and humoral responses to the middle but not to the large hepatitis B virus surface antigen in mice. *Hepatology* 1998;28:202-10.
207. *Geissler M, Tokushige K, Wakita T, Zurawski VR, Wands JR.* Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs. *Vaccine* 1998;16:857-67.
208. *Tanaka S, Akiyoshi T, Mori M, Wands JR, Sugimachi K.* A novel frizzled gene identified in human esophageal carcinoma mediates APC/ $\beta$ -catenin signals. *Proc Natl Acad Sci USA* 1998;95:10164-9.
209. *Tanaka S, Mori M, Akiyoshi T, Tanaka Y, Mafune K, Wands JR, Sugimachi K.* A novel variant of human Grb7 is associated with invasive esophageal carcinoma. *J Clin Invest* 1998;102:821-7.
210. *Yasui K, Wakita T, Tsukiyama-Kohara K, Funahashi SI, Ichikawa M, Kajita T, Moradpour D, Wands JR, Kohara M.* The native form and maturation process of hepatitis C virus core protein. *J Virol* 1998;72:6048-55.
211. *Moradpour D, Wakita T, Wands JR, Blum HE.* Tightly regulated expression of the entire hepatitis C virus structural region in continuous human cell lines. *Biochem Biophys Res Commun* 1998;246:920-4.
212. *zu Putlitz J, Wieland S, Blum HE, Wands JR.* Antisense RNA complementary to hepatitis B virus specifically inhibits viral replication. *Gastroenterology* 1998;115:702-13.
213. *Encke J, zu Putlitz J, Heintges T, Wands JR.* Total chemical synthesis of the 3' untranslated region of the hepatitis C virus with long oligodeoxynucleotides. *J Virol Methods* 1998;74:117-21.
214. *Encke J, zu Putlitz J, Geissler M, Wands JR.* Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. *J Immunol* 1998;161:4917-23.
215. *Mohr L, Tanaka S, Wands JR.* Ethanol inhibits hepatocyte proliferation in insulin receptor substrate 1 transgenic mice. *Gastroenterology* 1998;115:1558-65.

216. *zu Putlitz J, Skerra A, Schroder CH, Zentgraf H, Wands JR.* Cloning, bacterial synthesis, and characterization of immunoglobulin variable regions of a monoclonal antibody specific for the hepatitis B virus X protein. *Gene* 1998;221:143-9.
217. *Banerjee K, Mohr L, Wands JR, de la Monte SM.* Ethanol inhibition of insulin signaling in hepatocellular carcinoma cells. *Alcohol Clin Exp Res* 1998;22:2093-101.
218. *Etiene D, Ganju N, Kraft J, Hyman BT, Gomez-Isla T, Hedley-Whyte ET, Wands JR, de la Monte SM.* Cerebrovascular pathology contributes to the heterogeneity of Alzheimer's disease. *J Alzheimer Dis* 1998; 1:119-134.
219. *Sohn YK, Ganju N, Bloch KD, Wands JR, de la Monte SM.* Neuritic sprouting with aberrant expression of the nitric oxide synthase III gene in neurodegenerative diseases. *J Neurol Sci* 1999;162:133-51.
220. *Mohr L, Schauer JJ, Boutin RH, Moradpour D, Wands JR.* Targeted gene transfer to hepatocellular carcinoma cells in vitro using a novel monoclonal antibody-based gene delivery system. *Hepatology* 1999;29:82-9.
221. *Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR.* Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. *J Clin Invest* 1999;103:341-5.
222. *zu Putlitz J, Tong S, Wands JR.* A short region in the genome of hepatitis B virus is critical for maintenance of high transcript levels. *Virology* 1999;254:245-56.
223. *zu Putlitz J, Skerra A, Wands JR.* Intracellular expression of a cloned antibody fragment interferes with hepatitis B virus surface antigen secretion. *Biochem Biophys Res Commun* 1999;255:785-91.
224. *Wakita T, Moradpour D, Tokushihge K, Wands JR.* Antiviral effects of antisense RNA on hepatitis C virus RNA translation and expression. *J Med Virol* 1999;57:217-22.
225. *Ince N, Wands JR.* The increasing incidence of hepatocellular carcinoma. *N Engl J Med* 1999;340:798-9.
226. *Geissler M, Bruss V, Michalak S, Hockenjos B, Ortmann D, Offensperger WB, Wands JR, Blum HE:* Intracellular retention of hepatitis B virus surface proteins reduces interleukin-2 augmentation after genetic immunizations. *J Virol* 1999;73:4284-92.
227. *zu Putlitz J, Lanford RE, Carlson RI, Notvall L, de la Monte SM, Wands JR.* Properties of monoclonal antibodies directed against hepatitis B virus polymerase protein. *J Virol* 1999;73:4188-96.
228. *de la Monte SM, Ganju N, Wands JR.* Microtiter immunocytochemical ELISA assay. *Biotechniques* 1999;26:1073-6.

229. *zu Putlitz J, Wands JR.* Specific inhibition of hepatitis B virus replication by sense RNA. *Antisense Nucleic Acid Drug Dev* 1999;9:241-52.
230. *zu Putlitz J, Yu Q, Burke JM, Wands JR.* Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus. *J Virol* 1999;73:5381-7.
231. *de la Monte SM, Ganju N, Tanaka S, Banerjee K, Karl PJ, Brown NV, Wands JR.* Differential effects of ethanol on insulin-signaling through the insulin receptor substrate-1. *Alcohol Clin Exp Res* 1999;23:770-7.
232. *Tong S, Li J, Wands JR.* Carboxypeptidase D is an avian hepatitis B virus receptor. *J Virol* 1999;73:8696-702.
233. *Li J, Tong S, Wands JR.* Identification and expression of glycine decarboxylase (p120) as a duck hepatitis B virus pre-S envelope-binding protein. *J Biol Chem* 1999;274:27658-65.
234. *Encke J, zu Putlitz, J, Wands JR.* DNA vaccines. *Intervirology* 1999;42:117-24.
235. *de la Monte SM, Ghanbari H, Ghanbari K, Averbach P, Wands JR.* AD7c-NTP biomarker for Alzheimer's disease. *Alzheimers Reports* 1999;2:327-32.
236. *Heintges T, zu Putlitz J, Wands JR.* Characterization and binding of intracellular antibody fragments to the hepatitis C virus core protein. *Biochem Biophys Res Commun* 1999;263:410-8.
237. *Encke J, Wands JR.* Ethanol inhibition: the humoral and cellular immune response to hepatitis C virus NS5 protein after genetic immunization. *Alcohol Clin Exp Res* 2000;7:1063-9.
238. *Mohr L, Shankara S, Yoon SK, Krohne TU, Geissler M, Roberts B, Blum HE, Wands JR.* Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the *Escherichia coli* purine nucleoside phosphorylase gene. *Hepatology* 2000;31:606-14.
239. *Ince N, de la Monte SM, Wands JR.* Overexpression of human aspartyl (asparaginyl)  $\beta$ -hydroxylase is associated with malignant transformation. *Cancer Res* 2000;60:1261-6.
240. *Tanaka S, Sugimachi K, Kawaguchi H, Saeki H, Ohno S, Wands JR.* Grb7 signal transduction protein mediates metastatic progression of esophageal carcinoma. *J Cell Physiol* 2000;183:411-5.

241. *de la Monte SM, Ganju N, Banerjee K, Brown NV, Luong T, Wands JR.* Partial rescue of ethanol-induced neuronal apoptosis by growth factor activation of phosphoinositol-3-kinase. *Alcohol Clin Exp Res* 2000;24:716-26.
242. *Tanaka S, Sugimachi K, Shirabe K, Shimada M, Wands JR.* Expression and antitumor effects of TRAIL in human cholangiocarcinoma. *Hepatology* 2000;32:523-27.
243. *de la Monte SM, Sohn YK, Etienne D, Kraft J, Wands JR.* Role of aberrant nitric oxide synthase-3 expression in cerebrovascular degeneration and vascular-mediated injury in Alzheimer's disease. *Ann NY Acad Sci* 2000;903:61-71.
244. *Yoon SK, Mohr L, O'Riordan CR, Lachapelle A, Armentano D, Wands JR.* Targeting a recombinant adenovirus vector to HCC cells using a bifunctional Fab-antibody conjugate. *Biochem Biophys Res Commun* 2000;272:497-504.
245. *de la Monte SM, Lu BX, Sohn YK, Etienne D, Kraft J, Ganju N, Wands JR.* Aberrant expression of nitric oxide synthase III in Alzheimer's disease: relevance to cerebral vasculopathy and neurodegeneration. *Neurobiol Aging* 2000;21:309-19.
246. *de la Monte SM, Luong T, Neely TR, Robinson D, Wands JR.* Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. *Lab Invest* 2000;80:1323-35.
247. *Mohr L, Rainov N, Mohr UG, Wands JR.* Rabbit cytochrome P450 4B1: a novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma. *Cancer Gene Ther* 2000; 7:1008-14.
248. *de la Monte SM, Ganju N, Feroz T, Luong T, Banerjee K, Cannon J, Wands JR.* Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells. *J Alz Dis* 2000;2:261-81.
249. *de la Monte SM, Neely TR, Cannon J, Wands JR.* Oxidative stress and hypoxia-like injury cause Alzheimer-type molecular abnormalities in CNS neurons. *Cell Mol Life Sci* 2000;57:1471-81.
250. *zu Putlitz J, Encke J, Wands JR.* Cytotoxic T-cell responses against hepatitis B virus polymerase induced by genetic immunization. *J Hepatology* 2000;33:986-91.
251. *de la Monte SM, Wands JR.* Alzheimer-associated neuronal thread protein-induced apoptosis and impaired mitochondrial function in human central nervous system-derived neuronal cells. *J Neuropathol Exp Neurol* 2001;60:195-207.
252. *Mohr L, Yoon SK, Eastman SJ, Chu O, Scheule RK, Scaglioni PP, Geissler M, Heintges T, Blum HE, Wands JR.* Cationic liposome-mediated gene delivery to the liver and to hepatocellular carcinomas in mice. *Hum Gene Ther* 2001;12:799-809.

253. *Tanaka S, Ueo H, Mafune K, Mori M, Wands JR, Sugimachi K.* A novel isoform of human fibroblast growth factor 8 is induced by androgens and associated with progression of esophageal carcinoma. *Dig Dis Sci* 2001;46:1016-21.
254. *de la Monte SM, Wands JR.* Mitochondrial DNA damage and impaired mitochondrial function contribute to apoptosis of insulin-stimulated ethanol-exposed neuronal cells. *Alcohol Clin Exp Res* 2001;25:898-906.
255. *de la Monte SM, Wands JR.* Ethanol-induced mitochondrial DNA damage and impaired mitochondrial function in neuronal cells. *Alcohol Clin Exp Res* 2001 96:1-6.
256. *de la Monte SM, Wands JR.* Neurodegeneration changes in primary central nervous system neurons transfected with the Alzheimer-associated neuronal thread protein gene. *Cell Mol Life Sci* 2001;58:844-9.
257. *Krohne TU, Shankara S, Geissler M, Roberts BL, Wands JR, Blum HE, Mohr L.* Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. *Hepatology* 2001;34:511-8.
258. *Yoon SK, Armentano D, Wands JR, Mohr L.* Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice. *Cancer Gene Therapy* 2001;8:573-579.
259. *Mauch C, Grimm C, Meckel S, Wands JR, Blum HE, Roggendorf M, Geissler M.* Induction of cytotoxic T lymphocyte responses against hepatitis delta virus antigens which protect against tumor formation in mice. *Vaccine* 2001;20:170-80.
260. *Spangenberg HC, Lee HB, Li J, Tan F, Skidgel R, Wands JR, Tong S.* A short sequence within domain C of duck carboxypeptidase D is critical for duck hepatitis B virus binding and determines host specificity. *J Virol* 2001;75:10630-42.
261. *Spangenberg HC, Wands JR.* Ribozymes and hepatitis B virus. *J Gastroenterol Hepatol* 2001 16:1084-5.
262. *Heintges T, Encke J, zu Putlitz J, Wands JR.* Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor. *J Med Virol* 2001;65:671-80.
263. *de la Monte SM, Neely TR, Cannon J, Wands JR.* Ethanol impairs insulin-stimulated mitochondrial function in cerebellar granule neurons. *Cell mol Life Sci* 2001;48:1950-60.
264. *Tanaka S, Sugimachi K, Maehara Si S, Harimoto N, Shirabe K, Wands JR, Sugimachi K.* Oncogenic signal transduction and therapeutic strategy for hepatocellular carcinoma. *Surgery* 2002;131:S142-7.

265. *de la Monte SM, Wands JR.* The ad7c-ntp neuronal thread protein biomarker for detecting Alzheimer's disease. *Front Biosci* 2002;7:D989-96.
266. *Tanaka S, Sugimachi K, Yamashita Yi Y, Ohga T, Shirabe K, Shimada M, Wands JR, Sugimachi K.* Tie 2 vascular endothelial receptor expression and function in hepatocellular carcinoma. *Hepatology* 2002;35:861-7.
267. *de la Monte SM, Wands JR.* Chronic gestational exposure to ethanol impairs insulin-stimulated survival and mitochondrial function in cerebellar neurons. *Cell Mol Life Sci* 2002;59:882-93.
268. *Sepe PS, Lahousse SA, Gemelli B, Chang H, Maeda T, Wands JR, de la Monte SM.* Role of aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility. *Lab Invest* 2002;82:881-91.
269. *Palumbo KS, Wands JR, Safran H, King T, Carlson RI, de la Monte SM.* Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. *Pancreas* 2002;25:39-44.
270. *de la Monte, SM, Lahousse SA, Carter J, Wands JR.* ATP luminescence-based motility-invasion assay. *Biotechniques* 2002;33:98-104.
271. *Dumoulin FL, von dem Bussche A, Li J, Khamzina L, Wands JR, Sauerbruch T, Spengler U.* Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. *Virology* 2003;305:260-6.
272. *Encke J, zu Putlitz J, Stremmel W, Wands JR.* CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization. *Arch Virol* 2003;148:435-48.
273. *Molina PE, Hock JB, Nelson S, Guidot DM, Lang CH, Wands JR, Crawford JM.* Mechanisms of alcohol-induced tissue injury. *Alcohol Clin Exp Res* 2003;27:563-75.
274. *Tanaka S, Sugimachi K, Yamashita Y, Shirabe K, Shimada M, Wands JR, Sugimachi K.* Angiogenic switch as a molecular target of malignant tumors. *J Gastroenterol* 2003;38:93-7.
275. *Xu J, Yeon JE, Chang H, Tison G, Chen GJ, Wands JR, de la Monte SM.* Ethanol impairs insulin-stimulated neuronal survival in the developing brain: role of PTEN phosphatase. *J Biol Chem* 2003;278:26929-37.
276. *Maeda T, Sepe P, Lahousse S, Tamaki S, Enjoji M, Wands JR, de la Monte SM.* Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. *J Hepatol* 2003;38:615-22.

277. *Tanaka S, Sugimachi K, Kameyama T, Maehara S, Shirabe K, Shimada M, Wands JR, Maehara Y.* Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. *Hepatology* 2003;37:1122-9.
278. *Wiedmann M, Tamaki S, Silberman R, de la Monte SM, Cousens L, Wands JR.* Constitutive over-expression of the insulin receptor substrate-1 causes functional up-regulation of Fas receptor. *J Hepatol* 2003;38:803-10.
279. *Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakakibara M, Takehara T, Fujimoto J, Hori M, Wands JR, Hayashi N.* Involvement of p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. *Cancer* 2003;97:3017-26.
280. *Khamzina L, Gruppuso PA, Wands JR.* Insulin signaling through IRS-1 and IRS-2 in normal liver development. *Gastroenterology* 2003;125:572-85.
281. *Yeon JE, Califano S, Xu J, Wands JR, de la Monte SM.* Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. *Hepatology* 2003;38:703-14.
282. *Ahn SH, Kramvis A, Kawai S, Spangenberg HC, Li J, Kimbi G, Kew M, Wands JR, Tong S.* Sequence variation upstream of precore translation initiation codon reduces hepatitis B virus e antigen production. *Gastroenterology* 2003;125:1370-8.
283. *Parekh S, Zoulim F, Ahn SH, Tsai A, Li J, Kawai S, Khan N, Trepo C, Wands JR, Tong S.* Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. *J Virol* 2003;77:6601-12.
284. *Aloman C, Wands JR.* Resistance of adefovir dipivoxil: a case for combination therapy? *Hepatology* 2003;38:1584-7.
285. *de la Monte SM, Chen GJ, Rivera E, Wands JR.* Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells. *Cell Mol Life Sci* 2003;60:2679-91.
286. *Li J, Tong S, Lee HB, Perdigoto AL, Spangenberg HC, Wands JR.* Glycine decarboxylase mediates a postbinding step in duck hepatitis B virus infection. *J Virol* 2004;78:1873-81.
287. *Horimoto M, Fulop P, Derdak Z, Wands JR, Baffy G.* Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice. *Hepatology* 2004;39:386-92.
288. *Khan N, Guarnieri M, Ahn SH, Li J, Zhou Y, Bang G, Kim KH, Wands JR, Tong S.* Modulation of hepatitis B virus secretion by naturally occurring mutations in the S gene. *J Virol* 2004;78:3262-70.



289. *Giannone PJ, Abu Dayyeh BK, Bienieki TC, Wands JR, Gruppuso PA.* Targeted hepatic overexpression of human IRS-1: postnatal effects in the developing mouse. *Biochim Biophys Acta* 2004;1672:112-9.
290. *de la Monte SM, Wands JR.* Alzheimer-associated neuronal thread protein mediated cell death is linked to impaired insulin signaling. *J Alzheimers Dis* 2004;6:231-42.
291. *Yoon SK, Lim NK, Ha SA, Park YG, Choi JU, Chung KW, Sun HS, Choi MJ, Chung J, Wands JR, Kim JW.* The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. *Cancer Res* 2004;65:5434-41.
292. *Horimoto M, Resnick M, KonKin T, Routhier J, Wands JR, Baffy G.* Expression of uncoupling protein-2 in human colon cancer. *Clin Cancer Res* 2004;10:6203-7.
293. *Wands JR.* Prevention of hepatocellular carcinoma. *N Engl J Med* 2004;351:1567-70.
294. *Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, von Dem Bussche A, Kew MC, Trepo C, Wands JR.* Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. *Gastroenterology* 2004;127:1110-22.
295. *Mohr L, Yeung A, Aloman C, Wittrup D, Wands JR.* Antibody-directed therapy for human hepatocellular carcinoma. *Gastroenterology* 2004;127(5 Suppl 2):S225-31.
296. *Maeda T, Taguchi K, Aishima S, Shimada M, Hintz D, Larusso N, Gores G, Tsuneyoshi M, Sugimachi K, Wands JR, de la Monte, SM.* Clinicopathological correlates of aspartyl (asparaginy)- $\beta$ -hydroxylase overexpression in cholangiocarcinoma. *Cancer Detect Prev.* 2004;28:313-8.
297. *Gehring S, Gregory SH, Kuzushita N, Wands JR.* Type 1 interferon augments DNA-based vaccination against hepatitis c virus core protein. *J Med Virol* 2005;75:249-57.
298. *Steen E, Terry BM, J Rivera E, Cannon JL, Neely TR, Tavares R, Xu SJ, Wands JR, de la Monte SM.* Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes? *J Alzheimers Dis* 2005;7:63-80.
299. *de la Monte SM, Wands JR.* Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system. Relevance to Alzheimer's disease. *J Alzheimers Dis* 2005;7:45-61.
300. *Fukutomi T, Zhou Y, Kawai S, Eguchi H, Wands JR, Li JS.* Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. *Hepatology* 2005;41:1096-105.
301. *de la Monte SM, Xu XJ, Wands JR.* Ethanol inhibits insulin expression and actions in the developing brain. *Cell Mol Life Sci* 2005;62:1131-45.

302. *Tong S, Kim KH, Chante C, Wands JR, Li JS.* Hepatitis B virus e antigen variants. *Int J Med Sci* 2005; 2:2-7.
303. *Merle P, Kim M, Herrmann M, Gupte A, Lefrancois L, Califano S, Trepo C, Tanaka S, Vitvitski L, Monte SD, Wands JR.* Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. *J Hepatol* 2005;43:854-62.
304. *Tanaka S, Wands JR, Arii S.* Induction of angiopoietin-2 gene expression by COX-2: a novel role for COX-2 inhibitors during hepatocarcinogenesis. *J Hepatol* 2006;44:233-5.
305. *Kuzushita N, Gregory SH, Gehring S, Wands JR.* Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens. *Gastroenterology* 2006;130:453-64.
306. *Guarnieri M, Kim KH, Bang G, Li J, Zhou Y, Tang X, Wands JR, Tong S.* Point mutations upstream of hepatitis B virus core gene affect DNA replication at the step of core protein expression. *J Virol* 2006;80:587-95.
307. *Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM.* Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. *J Alzheimers Dis* 2006;8:247-68.
308. *Lee HC, Kim M, Wands JR.* Wnt/Frizzled signaling in hepatocellular carcinoma. *Front Biosci* 2006;11:1901-15.
309. *Derdak Z, Fulop P, Sabo E, Tavares R, Berthiaume EP, Resnick MB, Paragh G, Wands JR, Baffy G.* Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-(kappa) B activation and oxidative stress. *Carcinogenesis* 2006; 27:956-61.
310. *de la Monte SM, Tamaki S, Cantarini MC, Ince N, Wiedmann M, Cater JJ, Lahousse SA, Califano S, Maeda T, Ueno T, D'Errico A, Trevisani F, Wands JR.* Aspartyl-(asparaginy) beta-hydroxylase regulates hepatocellular carcinoma invasiveness. *J Hepatol* 2006;44:971-83.
311. *Branda M, Wands JR.* Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. *Hepatology* 2006;43:891-902.
312. *Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM.* Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. *J Alzheimers Dis* 2006;9:13-33.
313. *Cantarini MC, de la Monte, SM, Pang M, Tong M, D'Errico A, Trevisani F, Wands JR.* Aspartyl-asparagyl beta-hydroxylase overexpression in human hepatoma is linked to

- activation of insulin-like growth factor and notch signaling mechanisms. *Hepatology* 2006;44:446-57.
314. *de la Monte SM, Wands JR.* Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. *J Alzheimers Dis* 2006 Jun;9(2):167-81.
  315. *Soscia SJ, Tong M, Xu XJ, Cohen AC, Chu J, Wands JR, de la Monte SM.* Chronic gestational exposure to ethanol causes insulin and IGF resistance and impairs acetylcholine homeostasis in the brain. *Cell Mol Life Sci.* 2006;63:2039-56.
  316. *Brown LA, Cook RT, Jerrells TR, Kolls JK, Nagy LE, Szabo G, Wands JR.* Acute and chronic alcohol abuse modulate immunity. *Alcohol Clin Exp Res.* 2006;30:1624-31.
  317. *Fulop P, Derdak Z, Sheets A, Sabo E, Berthiaume EP, Resnick MB, Wands JR, Paragh G, Baffy G.* Lack of UCP2 reduced Fas-mediated liver injury in ob/ob mice and reveals importance of cell-specific UCP2 expression. *Hepatology* 2006;44:592-60.
  318. *Szabo G, Aloman C, Polyak SJ, Weinman SA, Wands JR, Zakhari S.* Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity. *Alcohol Clin Exp Res* 2006; 709-19.
  319. *de la Monte SM, Tong M, Lester-Coll N, Plater M, Wands JR.* Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. *J Alzheimers Dis* 2006;10:89-109.
  320. *Fu X, Beer DG, Behar J, Wands JR, Lambeth D, Cao W.* cAMP-response element-binding protein mediates acid-induced NADPH oxidase NOX5-S expression in Barrett esophageal adenocarcinoma cells. *J Biol Chem* 2006; 281:20368-82.
  321. *Lee HC, Tian B, Sedivy J, Wands JR, Kim M.* Loss of raf kinase inhibitor protein promotes cell proliferation and migration of human hepatocellular carcinoma. *Gastroenterology* 2006;131:1208-17.
  322. *Lahousse SA, Carter JJ, Xu XJ, Wands JR, de la Monte SM.* Differential growth factor regulation of aspartyl-(asparaginyl)-beta-hydroxylase family genes in SH-Sy5y human neuroblastoma cells. *Cell Biol* 2006;7:41
  323. *Aloman C, Gehring S, Wintermeyer P, Kuzushita N, Wands JR.* Chronic ethanol consumption impairs cellular immune responses against HCV NS5 protein due to dendritic cell dysfunction. *Gastroenterology* 2007;132:698-708.
  324. *Wang J, de la Monte SM, Sabo E, Kethu S, Tavares R, Branda M, Simao L, Wands JR, Resnick MB.* Prognostic value of humbug gene overexpression in stage II colon cancer. *Hum Pathol* 2007;38:17-25.

325. Gundogan F, Elwood G, Greco D, Rubin LP, Par H, Carlson RI, Wands JR, de la Monte SM. Role of aspartyl-(asparaginyl) beta-hydroxylase in placental implantation. Relevance to early pregnancy loss. *Hum Pathol* 2007;39:50-9.
326. Si J, Fu X, Behar J, Wands J, Beer DG, Souza RF, Spechler SJ, Lambeth D, Cao W. NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-k-b in Barrett's esophageal adenocarcinoma cells. *J Biol Chem* 2007;282:6244-55.
327. de la Monte SM, Jhaveri A, Maron BA, Wands JR. Nitric oxide synthase 3-mediated neurodegeneration after intracerebral gene delivery. *N Neuropathol Exp Neurol* 2007;66:272-83.
328. Wintermeyer P, Wands JR. Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments. *J Gastroenterol* 2007;42:424-32.
329. Ronis MJ, Wands JR, Badger TM, de la Monte SM, Lang CH, Clissenorff J. Alcohol-induced disruption of endocrine signaling. *Alcohol Clin Exp Res* 2007;31:1269-85.
330. Cohen AC, Tong M, Wands JR, de la Monte SM. Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. *Alcohol Clin Exp Res* 2007;31:1558-73.
331. Li K, Zoulim F, Pichoud C, Kwei K, Villet S, Wands J, Li J, Tong S. Critical role of the 36-nucleotide insertion in hepatitis B virus genotype G in core protein expression, genome replication, and virion secretion. *J Virol* 2007;81:9202-15.
332. Laperle CM, Wintermeyer P, Wands JR. Propagation based differential phase contrast imaging and tomography of murine liver tissue with a laser plasma x-ray source. *Appl Phys Lett* 2007; 91:173901-3.
333. Wands JR. Hepatocellular carcinoma and sex. *N Engl J Med* 2007;357:1974-6.
334. Yeung YA, Finney AH, Koyrakh LA, Lebowitz MS, Ghanbari HA, Wands JR, Wittrup KD. Isolation and characterization of human antibodies targeting human aspartyl (asparaginyl)  $\beta$ -hydroxylase. *Human Antibodies* 2007;16:163-76.
335. He J, de la Monte S, Wands JR. Acute ethanol exposure inhibits insulin signaling in the liver. *Hepatology* 2007;46:1791-800.
336. Gundogan F, Elwood G, Longato L, Tong M, Feijoo A, Carlson RI, Wands JR, de la Monte SM. Impaired placentation in fetal alcohol syndrome. *Placenta* 2008;29:148-57.

337. *Gehring S, Gregory SH, Wintermeyer P, San Martin M, Aloman C, Wands JR.* Generation and characterization of an immunogenic dendritic cell population. *J Immunol Methods* 2008;332:18-30.
338. *Sheets AR, Fulop P, Derdak Z, Kassai A, Sabo E, Mark NM, Paragh G, Wands JR, Baffy G.* Uncoupling protein-2 modulates the lipid metabolic response to fasting in mice. *Am J Physiol Gastrointest Liver Physiol* 2008;294:1017-24.
339. *Kim M, Lee HC, Tsedensodnom O, Hartley R, Lim YS, Yu E, Merle P, Wands JR.* Functional interaction between Wnt3 and Frizzled-7 leads to activation of catenin signaling pathway in hepatocellular carcinoma cells. *J Hepatol* 2008;48:780-91.
340. *Bengochea A, deSouza MM, Lefrancois L, LeRoux E, Beseme S, Chemin I, Kim M, Wands JR, Trepo C, Hainaut P, Scoazec JY, Vitvitski L, Merle P.* Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. *Br J Cancer* 2008;99:143-50.
341. *Carter JJ, Tong M, Silbermann E, Lahousse SA, Ding FF, Longato L, Roper N, Wands JR, de la Monte SM.* Ethanol impaired neuronal migration is associated with reduced aspartyl-asparaginyl- $\beta$ -hydroxylase expression. *Acta Neuropathol* 2008;116:303-15.
342. *de la Monte SM, Yeon JE, Tong M, Longato L, Chaudhry R, Pang MY, Duan K, Wands JR.* Insulin resistance in experimental alcohol-induced liver disease. *J Gastroenterol Hepatol* 2008;23:e477-86.
343. *Derdak Z, Mark NM, Beldi G, Robson SC, Wands JR, Baffy G.* The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. *Cancer Res* 2008;68:2813-9.
344. *Trevisani F, Cantarini MC, Wands JR, Bernardi M.* Recent advances in the natural history of hepatocellular carcinoma. *Carcinogenesis* 2008;29:1299-1305.
345. *Longato L, de la Monte SM, Califano S, Wands JR.* Synergistic premalignant effects of chronic ethanol exposure and insulin 1 overexpression in the liver. *Hepatol Res* 2008;38:940-53.
346. *de la Monte SM, Tong M, Cohen AC, Sheedy D, Harper C, Wands JR.* Insulin and insulin-like growth factor resistance in alcoholic neurodegeneration. *Alcohol Clin Exp Res* 2008;32:1630-44.
347. *Mohr L, Banerjee K, Kleinschmidt M, Bartolome-Rodriguez MM, Wands JR.* Transgenic overexpression of insulin receptor substrate 1 in hepatocytes enhances hepatocellular proliferation in young mice only. *Hepatol Res* 2008;38:1233-40.
348. *Laperle CM, Hamilton TJ, Wintermeyer P, Walker EJ, Shi D, Anastasio MA, Derdak Z, Wands JR, Diebold G, Rose-Petruck C.* Low density contrast agents for x-ray phase

- contrast imaging: the use of ambient air for x-ray angiography of excised murine liver tissue. *Phys Med Biol* 2008;53:6911-23.
349. *Gehring S, Gregory SH, Wintermayer P, Aloman C, Wands JR.* Generation of immune responses against HCV by dendritic cells containing NS5 protein-coated microparticles. *Clin Vaccine Immunol* 2009;16:163-71.
  350. *Kim E, Li K, Lieu C, Tong S, Kawai S, Fukutomi T, Zhou Y, Wands JR, Li J.* Expression of apolipoprotein C-IV is regulated by Ku antigen/peroxisome proliferator-activated receptor gamma complex and correlates with liver steatosis. *J Hepatol* 2008;49:787-98.
  351. *Luu M, Sabo E, de la Monte SM, Greaves W, Wang J, Tavares R, Simao L, Wands JR, Resnick MB, Wang L.* Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. *Hum Patol* 2009;40:639-44.
  352. *Tsai A, Kawai S, Kwei Km Gewaily D, Hutter A, Tong DR, Li J, Wands JR, Tong S.* Chimeric constructs between two hepatitis B virus genomes confirm transcriptional impact of core promoter mutations and reveal multiple effects of core gene mutations. *Virology* 2009;387:364-72.
  353. *Addolorato G, Russell M, Albano E, Haber PS, Wands JR, Leggio L.* Understanding and treating patients with alcoholic liver cirrhosis: an update. *Alcohol Clin Exp Res* 2009;33:1136-44
  354. *Siu L, Foont J, Wands JR.* Hepatitis C virus and alcohol. *Seminars in Liver Disease.* NY: Thieme Medical Publ 2009;29:188-99.
  355. *Pang M, de la Monte SM, Longato L, Tong M, He J, Chaudhry R, Duan K, Ouh J, Wands JR.* PPAR $\delta$  agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. *J Hepatol* 2009;50:1192-1201.
  356. *Lyn-Cook LE, Laton M, Tong M, Silbermann E, Longato L, Jiao P, Mark P, Wands JR, Xu H, de la Monte SM.* Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. *J Alzheimers Dis* 2009;16:715-29.
  357. *de la Monte SM, Tong M, Carlson RI, Carter JJ, Longato L, Silbermann E, Wands JR.* Ethanol inhibition of aspartyl-asparaginyl-beta-hydroxylase in fetal alcohol spectrum disorder: otential link to the impairments in central nervous system neuronal migration. *Alcohol* 2009;43:225-40.
  358. *Longato L, de la Monte SM, Kuzushita N, Horimoto M, Rogers AB, Slagle BL, Wands JR.* Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. *Hepatology* 2009;49:1935-43.

359. *Tong M, Neusner A, Longato L, Lawton M, Wands JR, delaMonte SM.* Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, NASH, and Alzheimer's disease. *J Alzheimers Dis* 2009;17:827-44.
360. *de la Monte SM, Longato L, Tong M, DeNucci S, Wands JR.* The liver brain axis of alcohol-mediated neurodegeneration: role of toxic lipids. *Int J Environ Res Publ Hlth* 2009;6:2055-75.
361. *Pritchard JR, Cosgrove BD, Hemann MT, Griffith LG, Wands JR, Lauffenburger DA.* Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. *Molec Cancer Ther* 2009;8:2183-9.
362. *de la Monte SM, Longato L, Tong M, Wands JR.* Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. *Curr Opin Investig Drugs* 2009;10:49-60.
363. *Garcia T, Li J, Sureau C, Ito K, Qin Y, Wands JR, Tong S.* Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion. *J Virol* 2009;83:11152-65.
364. *Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava J, Wing RR.* Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis (NASH). *Hepatology* 2010;51:121-9.
365. *Hong J, Behar J, Wands JR, Resnick M, DeLellis R, Lambeth D, Cao W.* Bile acid reflux contributes to development of esophageal adenocarcinoma via activation of phosphatidylinositol-specific phospholipase C and NADPH oxidase NOX5-S. *Cancer Research Can* 2010;70:1247-55.
366. *Wintermeyer P, Gehring S, Eken A, Wands JR.* Generation of cellular immune responses to HCV NS5 protein through in vivo activation of dendritic cells. *J Viral Hepat* 2010;17:705-13.
367. *von dem Bussche A, Machida R, Li K, Loevinsohn G, Khander A, Wang J, Wakita T, Wands JR, Li J.* Hepatitis C virus NS2 protein triggers endoplasmic reticulum stress and suppresses its own viral replication. *J Hepatol.* 2010;53:797-804.
368. *Hong J, Behar J, Resnick M, Wang LJ, Delellis RA, Lambeth D, Souza RF, Spechler SJ, Cao W.* Role of a novel bile acid receptor TFR5 in the development of esophageal adenocarcinoma. *Gut* 2010;59:170-80.
369. *Tong Y, Tong S, Zhao X, Wang J, Jun J, Park J, Wands JR, Li J.* Initiation of duck hepatitis B virus infection requires cleavage by a furin-like protease. *J Virol* 2010;84:4569-78.

370. *Toyama T, Lee HC, Koga H, Wands JR, Kim M.* Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration. *Mol Cancer Res* 2010;8:254-265.
371. *Sungarian A, Cielo D, Sampath P, Bowling N, Moskal P, Wands JR, de la Monte SM.* Potential role of thymosin- $\alpha$ 1 adjuvant therapy for glioblastoma. *J Oncol* 2009;2009:302084.
372. *Ito K, Qin Y, Guarnieri M, Garcia T, Kweil K, Mizokami M, Zhang J, Li J, Wands JR, Tong S.* Impairment of hepatitis B virus virion secretion by single amino acid substitutions in the small envelope protein and rescue by a novel glycosylation site. *J Virol* 2010 [Epub ahead of print].
373. *de la Monte SM, Tong M, Nguyen V, Setshedi M, Longato L, Wands JR.* Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. *J Alzheimer's Dis* 2010;21:967-84.
374. *de la Monte SM, Wands JR.* Acetaldehyde adducts in alcoholic liver disease. *Oxidative Med Cell Longev* 2010;3:178-85.
375. *Hong J, Resnick M, Behar J, Wang LJ, Wands JW, DeLellis RA, Souza RF, Spechler SJ, Cao W.* Acid-induced P16 hypermethylation contributes to development of esophageal adenocarcinoma via activation of NADH oxidase NOX5-S. *Am J Physiol Gastro, Liver Physiol* 2010;299:G697-706.
376. *He J, delaMonte SM, Wands JR.* The p85 $\beta$  regulatory subunit of P13K serves as a substrate for PTEN protein phosphatase activity during insulin mediated signaling. *Biochem & Biophys Res Commun* 2010 397:513-9.
377. *delaMonte SM, Wands JR.* Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. *J Alzheimers Dis* 2010 (accepted).
378. *delaMonte SM, Wands JR.* Role of central nervous system insulin resistance in fetal alcohol spectrum disorders. *J Popul Ther Clin Pharmacol* 2010;17:e390-404.
379. *Reilly EC, Wands JR, Brossay L.* Cytokine dependent and independent iNKG cell activation. *Cytokine* 2010 ;51:227-331.
380. *Szabo G, Wands JR, Eken A, Osna NA, Weinman SA, Machida K, Joe Wang H.* Alcohol and hepatitis C virus interactions in immune dysfunctions and liver damage. *Alcohol Clin Exp Res* 2010;34(10):1675-86.
381. *de la Monte SM, Tong M, Nguyen V, Setshedi M, Longato L, Wands JR.* Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. *J Alz Dis* 2010;21:967-84.



382. *Lawton M, Tong M, Gundogan F, de la Monte SM, Wands JR.* Aspartyl-(asparaginyl) beta-hydroxylase, hypoxia-inducible factor-1 $\alpha$ , and Notch cross-talk in regulating neuronal motility. *Oxid Med Cell Longev* 2010;3: 347-56.
383. *DeNucci SM, Tong M, Longato L, Lawton M, Setshedi M, Carlson RI, Wands JR, de la Monte SM.* Rat strain differences in susceptibility to alcohol-induced injury and hepatic insulin resistance. *Gastroenterol Res Pract* 2010;2010. Pii:312790.
384. *Setshedi M, Wands JR, de la Monte SM.* Acetaldehyde adducts in alcoholic liver disease. *Oxid Med Cell Longev* 2010;3:178-85.
385. *Ito K, Qin Y, Guarnieri M, Garcia T, Kwei K, Mizokami M, Zang J, Li J, Wands JR., Tong S.* Impairment of HBV virus virion secretion by single amino acid substitutions in the small envelope protein and rescue by a novel glycosylation site *J Virol* 2010;84:12850-61.
386. *Nambotin SB, Lefrancois L, Sainsily X, Berthillon P, Kim M, Wands JR, Chevallier M, Jalinot P, Scoazec JY, Trepo C, Zoulim F. Merle P.* Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. *J Hepatol* 2011; 54:288-99
387. *Derdak Z, Lang CH, Villegas KA, Tong M, Mark NM, de la Monte SM, Wands JR.* Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease. *J Hepatol* 2011;54:164-72.
388. *Qin Y, Zhang J, Garcia T, Ito K, Gutelius D, Li J, Wands JR, Tong S.* An improved method for rapid and efficient determination of genome replication and protein expression of clinical hepatitis B virus isolates *J Clin Microbiol* 2011;49:1226-33.
389. *Hong J, Resnick M, Behar J, Wands J, Wang LJ, DeLellis RA, Cao W.* Role of RAC1 in regulation of NOX5-S function in Barrett's esophageal adenocarcinoma cells. *Am J Physiol Cell Physiol* 2011;301:C413-20.
390. *Tsedensodnom O, Koga H, Rosenberg SA, Nambotin SB, Carroll JJ, Wands JR, Kim M.* Identification of T-cell factor-4 isoforms that contribute to the malignant phenotype of hepatocellular carcinoma cells. *Exp Cell Res* 2011;317:920-31.
391. *delaMonte SM, Pang M, Chaudhry R, Duan K, Longato L, Carter J, Ouh J, Wands JR.* Peroxisome proliferator-activated receptor agonist treatment of alcohol-induced hepatic insulin resistance. *Hepatol Res* 2011;41:386-98.
392. *Yan T, Li K, Li F, Su H, Mu J, Tong S, Patel M, Xia J, Wands JR, Wang H.* T1846 and A/G1913 are associated with acute or chronic liver failure in patients infected with hepatitis B virus genotypes B and C. *J Med Virol* 2011;83:996-1004.

393. Nambotin SB, Wands JR, Kim M. Points of therapeutic intervention along the wnt signaling pathway in hepatocellular carcinoma. *Anticancer Agents Med Chem* 2011;11:549-59
394. Eken A, Ortiz V, Wands JR. Ethanol inhibits antigen presentation by dendritic cells. *Clin Vaccine Immunol* 2011; 18:1157-66.
395. Zhou X, Li D, Resnick M, Behar J, Wands JR, Cao W. Signaling in H202 induced increase in cell proliferation in Barrett's esophageal adenocarcinoma cells. *J Pharm Exp Ther* 2011;339:218-27.
396. Nambotin SB, Wands JR, Kim M. Points of therapeutic intervention along the Wnt signaling pathway in hepatocellular carcinoma. *Anti-Cancer Agents in Medicinal Chem* 2011;11: 549-59.
397. Walker EJ, Rosenberg SA, Wands JR, Kim M. Role of Raf kinase inhibitor protein in hepatocellular carcinoma. *Forum on Immunopathol Dis Ther* 2011;2:195-204.
398. Nambotin SB, Lefrancois L, Sainsily X, Berthillon P, Kim M, Wands JR, Chevallier M, Jalinot P, Scoazec JY, Trepo C, Zoulim F, Merle P. Pharmacological inhibition of Frizzled 7 displays anti-tumor properties in hepatocellular carcinoma. *J Hepatol* 2011; 54:288-99.
399. Promrat K, Longato L, Wands JR, de la Monte SM. Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. *Hepatol Res* 2011;41:754-62.
400. Gutelius D, Li J, Wands JR, Tong S. Characterization of the pleiotropic effects of the genotype G-specific 36-nucleotide insertion in the context of other hepatitis B virus genotypes. *J Virol* 2011;85:13278-89.
401. Setshedi M, Longato L, Petersen DR, Ronis M, Chen WC, Wands JR, de la Monte SM. Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis. *Alcohol Clin Exp Res* 2011 35:2139-51.
402. Feng D, Eken A, Ortiz V, Wands JR. Chronic alcohol-induced liver disease inhibits dendritic cell function. *Liver Int* 2011;31:950-63.
403. Rand D, Ortiz V, Liu Y, Derdak Z, Wands JR, Taticek M, Rose-Petruck C. Nanomaterials for x-ray imaging: gold nanoparticle enhancement of x-ray scatter imaging of hepatocellular carcinoma. *Nano Lett* 2011;11:2678-83.

404. Longato L, Tong M, Wands JR, de la Monte SM. High fat diet induced hepatic steatosis and insulin resistance: role of dysregulated ceramide metabolism. *Hepatology Res* 2012;42:412-27.
405. Noda T, Shimoda M, Ortiz , Sirica AE, Wands JR. Immunization with aspartate-beta-hydroxylase-loaded dendritic cells produces antitumoreffects in a rat model of intrahepatic cholangiocarcinoma. *Hepatology* 2012;55:86-97.
406. Derdak Z, Villegas KA, Wands JR. Early growth response-2 transcription factor promotes hepatic fibrosis and steatosis in longterm ethanol-fed Long-Evans rats. *Liver Int* 2012;32(5):761-70.
407. Shimoda M, Tomimaru Y, Charpentier KP, Safran H, Carlson RI, Wands JR. Tumor progression-related transmembrane protein aspartate-beta-hydroxylase is a target for immunotherapy of hepatocellular carcinoma. *J Hepatol* 2012;56:1129-35.
408. de la Monte SM, Derdak Z, Wands JR. Alcohol, insulin resistance and the liver-brain axis. *J Gastroenterol Hepatol* 2012;27 Suppl 2:33-41.
409. Reilly EC, Thompson EA, Aspeslagh S, Wands JR, Elewaut D, Brossay L. Activated iNKT cells promote memory CD8+ T-cell differentiation during viral infection. *PLoS ONE* 2012;7(5):e37791.
410. Longato L, Ripp K, Setshedi M, Dostalek M, Akhlaghi F, Branda M, Wands JR, de la Monte SM. Insulin resistance, ceramide-accumulation, and endoplasmic reticulum stress in human chronic alcohol-related liver disease. *Oxid Med Cell Longev* (in press)
411. Koga H, Tsedensodnom O, Walker EJ, Lee HC, Kang MK, Yano H, Wands JR, Kim M. Loss of the SxxSS motif in a human T-cel factor 4 isoform confers hypoxia resistance to liver cancer: an oncogenic switch in the Wnt signaling. *PLoS ONE* 2012;7(6):e39981.
412. Nambotin S, Tomimaru Y, Merle P, Wands JR, Kim M. Functional consequences of WNT3/Frizzled7 mediated signaling in non-transformed hepatic cells. *Oncogenesis* (in press).

## OTHER PUBLICATIONS

### REVIEWS, CHAPTERS, EDITORIALS

1. *Wands JR, Alpert E.* Immunology of viral hepatitis. In: Mathiew A, Kahn B (eds). Immunological Aspects of Anesthesia and Surgical Practice. New York:Grun & Stratton, 1977:191-203.
2. *Wands JR, Koff RS, Isselbacher KJ.* Acute hepatitis. In: Thorn G et al. (eds). Harrison's Principles of Internal Medicine, 8<sup>th</sup> Edition. New York:McGraw-Hill, Inc. 1977:1600-4.
3. *Wands JR, Koff RS, Isselbacher KJ.* Chronic active hepatitis. In: Thorn G et al. (eds). Harrison's Principles of Internal Medicine, 8<sup>th</sup> Edition. New York:McGraw-Hill, Inc. 1977;1600-4.
4. *Popp JW, Wands JR.* Recent views on the recognition of hemochromatosis. In: Davidson CS (ed). Problems in Liver Disease. New York:Stratton Intercontinental Medical Book Corp. 1979:301-11.
5. *Wands JR.* Viral hepatitis and its effect on pregnancy. In: Jewett JF, Kitzmiller JL, Schoenbaum SC (eds). Clinical Obstetrics and Gynecology. Maryland:Harper & Row 1979:309-20.
6. *Wands JR.* Alcohol and the immune response. In: Majchrowicz E, Noble EP (eds). Pharmacology of Ethanol, Vol. 7. New York:Plenum Press 1979:363-73.
7. *Wands JR, Carter EA, Bucher NLR, Isselbacher KJ.* Effect of acute and chronic ethanol intoxication of hepatic regeneration. In: Thurman RG et al (eds). Advances in Experimental Medicine and Biology 1980;132:663-70.
8. *Klingenstein FJ, Wands JR.* Immunologic effector mechanisms in hepatitis B-negative chronic hepatitis. In: Thomas H, Miescher PA (eds). Seminars in Immunopathology 1980;3:317-29.
9. *Wands JR.* Viral hepatitis in the compromised host. In: Rubin HR, Young LS (eds). Clinical Approach to Infection in the Immuno-Compromised Host. New York:Plenum Press 1981.
10. *Zurawski VR, Delvillano BC, Wands JR.* Monoclonal antibodies to hepatitis B surface antigen. In: Hammering et al (eds). Monoclonal Antibodies and T-Cell Hybridomas. New York:Elsevier 1981;273-82.
11. *Klingenstein RJ, Wands JR.* The development of animal models in chronic active hepatitis. In: Cohen S, Soloway RD (eds). Contemporary Issues in Gastroenterology. New York:Churchill Livingston 1983:249-59.

12. *Wands JR.* CPC – Primary Biliary Cirrhosis. *N Engl J Med* 1982;307:44-50.
13. *Friedman L, Wands JR.* Cirrhosis. In: Conn HF (ed). *Current Therapy*. Philadelphia:WB Saunders Co. 1983;356-61.
14. *Friedman L, Wands JR.* Non-A, non-B hepatitis. In: Isselbacher KJ et al (eds). *Harrison's Principles of Internal Medicine*. New York:McGraw-Hill 1984;97-115.
15. *Wands JR, Ben-Porath E, Wong MA.* Use of monoclonal antibodies in the study of viral hepatitis. In: Chisari F (ed). *Advances in Hepatitis Research*. New York:Mason Publ. Co. 1984;110-22.
16. *Wands JR:* Non-A, non-B hepatitis (editorial). *Hepatology* 1984;3:542-7.
17. *Ben-Porath E, Wands JR.* Monoclonal antibodies as diagnostic probes in the etiology of hepatitis. *Seminars Liver Disease* 1984;4:76-88.
18. *Wands JR, Ben-Porath E, Wong Am.* Monoclonal antibodies and hepatitis B: A new perspective using highly sensitive and specific radioimmunoassay. In: Vyas GN, Dienstag JL, Hoofnagle JH (eds). *Viral Hepatitis and Liver Disease*. NY:Grune & Stratton 1984;543-59.
19. *Bellet DH, Ozturk M, Wands JR, Bidart JM, Assicot M, Troalen F, Bohoun C.* Monoclonal antibodies directed toward unique epitopes on human chorionic gonadotropin: an approach to the development of sensitive and specific radioimmunoassays. In: Bizollon CA (ed). *Monoclonal Antibodies and New Trends in Immunoassays*. Amsterdam:Elsevier 1984;43-52.
20. *Shouval D, Wands JR, Shafritz DA.* Immunotherapy of human hepatocellular carcinoma: molecular and cellular studies with monoclonal antibodies to hepatitis B viral determinants. In: Hadwick CM (Ed). *Receptors in Tumor Biology*. New York:Marcel Dekker Inc. 1986.
21. *Ben-Porath E, Fujita YK, Wands JR.* Hepatitis B monoclonal antibody testing. In: Popper H, Shaffner F (eds). *Progress in Liver Diseases*, Vol. VIII. NY:Grune & Stratton 1986.
22. *Smith A, Wands JR.* Hepatic failure. In: Parrillo J (ed.) *Current Therapy in Critical Care Medicine*. Philadelphia:BC Decker Inc. 1986.
23. *Takahashi H, Wands JR.* Development of monoclonal antibodies against hepatitis B virus. In: Young H, McMillan H (eds) *Immunodiagnosis of Sexually Transmissible Diseases with Polyclonal and Monoclonal Antibodies*. New York:Marcel Dekker Inc. 1987;451-73.

24. *Wilson B, Wands JR*: Recent advances in the biology and immunology of hepatitis B. In: Hodgson H (ed.) *Gastrointestinal Immunology*. Philadelphia:WB Saunders 1987;623-45.
25. *Dienstag JD, Wands JR, Isselbacher KJ*. Acute hepatitis. In: Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, Braunwald E (eds). *Harrison's Principles of Internal Medicine*, 12<sup>th</sup> Edition. NY:McGraw-Hill 1990;1322-37.
26. *Wands JR, Isselbacher KJ*. Chronic hepatitis. In: Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, Braunwald E (eds). *Harrison's Principles of Internal Medicine*, 12<sup>th</sup> Edition. NY:McGraw-Hill 1990;1337-40.
27. *Isselbacher KJ, Wands JR*. Tumors of the liver. In: Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, Braunwald E (eds.) *Harrison's Principles of Internal Medicine*, 12<sup>th</sup> Edition. NY:McGraw-Hill 1990;1350-2.
28. *Blum HE, Liang TJ, Wands JR*. Hepatitis B virus carrier and hepatocellular carcinoma. Falk Symposium #54 – Infectious Diseases of the Liver 1990;261-73.
29. *Takahashi H, Wands JR*. Studies on cell surface changes associated with transformation of human hepatocytes to the malignant phenotype and their role as potential immunotargeting sites. In: Tsuchiya M et al. (eds) *Frontiers of Mucosal Immunology*, Vol. 2. Holland:Elsevier Science Publ 1991;295-8.
30. *Takahashi H, Wands JR*. Prognosis of hepatocellular carcinoma: known to be poor, yet difficult to predict. *J Nucl Med* 1991;23:235-6.
31. *Wands JR, Liang TJ, Blum HE, Shafritz D*. The molecular pathogenesis of liver disease during persistent hepatitis B virus infection. In: Shafritz D (eds). *Seminars in Liver Disease – "Impact of Recombinant DNA Techniques in Liver Disease."* NY:Thieme Med Publ 1992.
32. *Hasegawa K, Wands JR*. Immunology of liver diseases. In: *Current Opinion in Gastroenterology*. Philadelphia:Current Science 1992;8:1002-8.
33. *Weizsaecker Fv, Blum H, Wands JR*. Detection of low level hepatitis B and hepatitis C virus genome in alcoholics. In: *Advances in the Biosciences*. England:Pergamon Press 1993;86:439-48.
34. *Moradpour D, Wands JR*. The molecular pathogenesis of hepatocellular carcinoma. *J Viral Hep* 1994;1:17-31.
35. *Wands JR, Bhavani K, Sasaki Y*. Effect of ethanol on tyrosyl phosphorylation of growth factor receptor substrates in the liver. In: Watson RR (ed). *Alcohol and Hormones* NJ:Humana Press 1995;245-59.

36. *Moradpour D, Wands JR.* Understanding hepatitis B virus infection (editorial). *N Engl J Med* 1995;332-1092.
37. *Moradpour D, Wands JR.* Hepatic oncogenesis. In: Zakim D, Boyer T (eds). *Hepatology*, 3<sup>rd</sup> Edition. Philadelphia:W.B. Saunders 1996;1490-1512.
38. *Scaglioni PP, Melegari M, Wands JR.* Recent advances in the molecular biology of hepatitis B virus. *Bailliere's Clinical Gastroenterology:International Practice and Research*. London:Bailliere Tindall 1996;10:207-25.
39. *Moradpour D, Wands JR, Blum HE.* Molecular biology of hepatitis B and C virus and hepatocellular carcinoma. *Mol Cancer Biol* 1996;3:875-904.
40. *Heintges T, Wands JR.* HCV: epidemiology and transmission. *Hepatology* 1997;27:521-6.
41. *von Weiszacker F, Blum HE, Wands JR.* Hammerhead ribozyme mediated cleavage of hepatitis B virus RNA. Scanlon KJ (ed). *Methods in Molecular Medicine*. MJ:Humana Press 1998.
42. *Geissler M, Gesien A, Wands JR.* Molecular mechanisms of hepatocarcinogenesis. In: Okuda K, Tabor E (eds). *Liver Cancer*. London:Churchill Livingstone 1997:59-88.
43. *Encke J, zu Putlitz J, Wands JR.* Viral hepatitis – update. *DNA Vaccines. Intervirology* 1999; 42:117-124.
44. *zu Putlitz J, Encke J, Wands JR.* The use of antisense and other molecular approaches to therapy of chronic viral hepatitis. *Viral Hepatitis Reviews* 1998;4:207-227.
45. *Wands JR, Okuda IC.* Hepatocellular Carcinoma. In: Berk PD (ed). *Seminars in Liver Disease*. NY:Thieme Medical Publishers 1999;19:233-4.
46. *Wands JR.* Hepatitis C Virus Induced Hepatocarcinogenesis. In: Dienes HP, Schirmacher P, Brechot C, Okuda K (eds.). *Chronic Hepatitis: New Concepts of Pathogenesis, Diagnosis and Treatment*. Boston:Kluwer Academic Publishers 2000:214-26.
47. *Spangenberg H, Wands JR.* Nucleic acid based antiviral approaches to HBV. In: *Frontiers in Viral Hepatitis* 2000
48. *Wands JR, Mohr L, Banerjee K, Ganju N, Tanaka S de la Monte S.* Ethanol and IRS-1 protein in the liver and brain. In: *NIAAA Research Monograph-35 Ethanol and Intracellular Signaling: From Molecules to Behavior*. Hoek JB, Gordon AS, Mochly-Rosen D, Zakhari S (eds.) 2001:75-104.

49. *Spangenberg H, Wands JR.* DNA-based vaccination, antisense strategies, and other molecular approaches. In: Textbook of Viral Hepatitis. Rio de Janeiro:Atheneu Hispanica Publ 2001.
50. *Wands JR, Fukutomi T.* Molecular biology and oncogenesis of hepatocellular carcinoma. In: Treatment of Liver Diseases. Arroyo V, Bosch J, Bruguera M, Rodes J, Sanchez Tapias JM (eds.). Spain:Masson Publ 2001.
51. *Wiedmann M, Wands JR.* Pathogenesis of hepatocellular carcinoma by hepatitis viruses. In: Hepatitis Viruses. Jing-Hsiung James Ou (ed). Kluwer Academic Publishers 2002.
52. *Wands JR.* Altered signal transduction in human hepatocellular carcinoma. Falk Workshop #127 Leipzig, Germany 2002: Malignant Tumours: Basic Concepts and Clinical Management. Berr F, Bruix J, Hauss J, Wands J, Wittekind Ch (Eds). The Netherlands:Kluwer Academic Publishers 2002:9 – 19.
53. *Moradpour D, Wands JR.* Molecular Pathogenesis of Hepatocellular Carcinoma. In: Hepatology: A Textbook of Liver Disease - 4<sup>th</sup> Edition. Zakim D and Boyer TD (eds). PA:WB Saunders (publ). Chapter 44 –2003:1333-54.
54. *Spangenberg HC, Wands JR.* Nucleic acid-based antiviral approaches to HBV. In: Frontiers in Viral Hepatitis. Schinazi RF, Sommadossi JP, Rice CM (eds). Elsevier 2003:139 – 156.
55. *Berthiaume E, Wands JR.* The molecular pathogenesis of cholangiocarcinoma. In: Seminars in Liver Disease NY:Thieme Medical Publishers 2004.
56. *Kim M, Wands JR.* Insulin Pathway. In: Signaling pathways in liver disease. Dufour JF, Clavien PA (eds). Germany:Springer Scientific 2004
57. *Promrat K, Wands JR.* Aetiology of fulminant hepatitis. In: Viral Hepatitis, 3<sup>rd</sup> Edition. Thomas H, Zuckerman A, Lemon S (eds). England:Blackwell Publishing 2005;651-65.
58. *Wands JR, Moradpour D.* Molecular pathogenesis of hepatocellular carcinoma. In: Hepatology: A Textbook of Liver Disease – 5<sup>th</sup> Edition. Boyer, Manns & Wright (eds). PA:WB Saunders (publ.) Chapter 10-2006:
59. *Kim M, Wands JR.* Insulin Pathway. In: Signaling Pathways in Liver Disease. Dufour JF, Clavien PA (eds). Germany:Springer Scientific 2008.
61. *Shimoda M, Wands JR.* Molecular biology of liver carcinogenesis and hepatitis. In: Jarnagin & Blumgart (eds). Blumgart's Surgery of the Liver, Biliary Tree, and Pancreas. Chapter 8C 2012.



62. Wands JR, Kim M. Signaling pathways in viral related pre-neoplastic liver disease and hepatocellular carcinoma. In: Wang XW, Grisham JW, Thorgeirsson SS (Eds). *Cancer Genetics: Molecular Genetics of Liver Neoplasia*. NY:Springer 2010;103-27.
63. Walker EJ, Rosenberg SA, Wands JR, Kim M. The role of raf kinase inhibitor protein in hepatocellular carcinoma. *Forum on Immunopathological Disease and Therapeutics*, Begell House, Inc.(Publ) 2011;2(2):195-204.
64. Lin C, Xu C, Wands JR. Clinical and diagnostic aspects of viral hepatitis. In: Thomas H, Zuckerman A, Lok A, Locarnini S (Eds). *Viral Hepatitis 4<sup>th</sup> Edition* 2012 (in press).

## PROCEEDINGS OF MEETINGS

1. *Elfenbein GJ, Anderson PN, Humphrey RL, Mullins GM, Sensenbrenner LL, Wands JR, Santos GW*. Immune system reconstitution following allogeneic bone marrow transplantation in man: a multiparameter analysis. *Transplant Proc* 1976;8:641-6.
2. *Santos GW, Elfenbein GJ, Anderson PN, Humphrey RL, Mullins G, Nordin AA, Wands JR*. Reconstitution of the immune system following allogeneic bone marrow transplantation in man. In: *Symposium on the Immunobiology of Bone Marrow Transplantation*, 1977.
3. *Thiers V, Fujita A, DeReus H, Takahashi H, Degott C, Schellekens H, Dutiss K, Tiollais P, Wands JR, Brechot C*. Transmission of HBV and related viruses from HBsAg negative, HBV-DNA and monoclonal anti-HBs positive sera to chimpanzees. In: Zucherman AJ (ed). *Proceedings of the 1987 International Symposium on Viral Hepatitis and Liver Disease*. NY:AR Liss, Inc. 1988;521-7
4. *Shouval D, Adler R, Wands JR, Eliaki M, Sela M, Hurwitz E*. Chemo-immunotherapy of human hepatoma by a conjugate between adriamycin and monoclonal anti-HBs. In: Zucherman AJ (ed). *Proceedings of the 1987 International Symposium on Viral Hepatitis and Liver Disease*. NY: AR Liss, Inc. 1988;783-5.
5. *Ackerman Z, Gazitt Y, Wands JR, Brechot C, Kew M, Shouval D*. Unmasking of circulating HBsAg following removal of immune complexes from serum of HBsAg negative patients with chronic liver disease and hepatocellular carcinoma. In: Zucherman AJ (ed). *Proceedings of the 1987 International Symposium on Viral Hepatitis and Liver Disease*. NY: AR Liss, Inc. 1988;791-4.
6. *Ozturk M, Berkwitz R, Wands JR*. Free subunits of human chorionic gonadotropin as markers of trophoblastic differentiation and malignancy. In: Bellet J, Bidart JM (eds). *Structure-Function Relationship of Gonadotropins*. Sero Symposium Publ. Raven Press 1990;65:285-96.

7. *Kremsdorf D, Thiers V, Garreau F, Nakajima E, Schellekens H, Wands JR, Sninsky J, Houghton M, Toillais P, Brechot C.* Nucleotide sequence analysis of hepatitis B virus genomes isolated from serologically negative patients. In: Hollinger FB, Lamon SM, Margolis HS (eds). *Viral Hepatitis and Liver Disease*. MD:Williams and Wilkins 1991;222-6.
8. *Takahashi H, Liang TJ, Blum HE, Li Zeniya M, Fujise K, Kameda H, Wands JR.* Identification of a low level hepatitis B viral genome in hepatitis B vaccine nonresponders in Japan. In: Hollinger FB, Lamon SM, Margolis HS (eds). *Viral Hepatitis and Liver Disease*. MD:Williams and Wilkins 1991;779-82.
9. *Blum HE, Galun E, Liang TJ, Hasegawa K, Wands JR.* Structure and biological characteristics of a naturally occurring pre-core/core hepatitis B virus mutant. In: Hollinger FB, Lamon SM, Margolis HS (eds). *Viral Hepatitis and Liver Disease*. MD:Williams and Wilkins 1991;861-5.
10. *Liang TJ, Blum HE, Takahashi H, Galun E, Wands JR.* Detection and transmission of low level HBV and variant infection. In: Hollinger FB, Lamon SM, Margolis HS (eds). *Viral Hepatitis and Liver Disease*. MD:Williams and Wilkins 1991;684-6.
11. *Pace RA, Scott SJ, Wands JR, Cooksley WG.* Structure of the hepatitis virus in Australian aborigines. In: Hollinger FB, Lamon SM, Margolis HS (eds). *Viral Hepatitis and Liver Disease*. MD:Williams and Wilkins 1991;231-4.
12. *Paterlini P, Gerken G, Khemeny F, Franco D, D'Errico A, Grigioni W, Wands JR, Kew M, Pisi E, Tiollais P, Brechot C.* Primary liver cancer in HBsAg negative patients: a study of HBV genome using the polymerase chain reaction. In: Hollinger FB, Lamon SM, Margolis HS (eds). *Viral Hepatitis and Liver Disease*. MD:Williams and Wilkins 1991;605-10.
13. *de la Monte S, Wands JR.* Increased levels of neuronal thread protein in cerebral tissue and cerebrospinal fluid of patients with probable and confirmed Alzheimer's disease. In: Corain B, Iqbal K, Nicolini M, Winblad B, Wisniewski H, Zatta P (eds). *Alzheimer's Disease: Advances in Clinical and Basic Research*. NY:John Wiley & Sons Ltd. 1993;73-82.
14. *Wands JR.* Clinical significance of hepatitis B viral variants. *Current Topics in Gastroenterology*. J Tokyo Women's Med College 1993;63:107-13.
15. *Wands JR, Scaglioni P, Melegari M.* Hepatitis B viral variants. *Falk Symposium 87. Acute and Chronic Liver Diseases: Molecular Biology and Clinics* 1996:12-26.
16. *Wands JR, Yoon SK, Melegari M, Scaglioni PP, Geissler M.* Gene therapy of viral hepatitis. In: Okuda K, Tabor E, Masson SA (eds). *Therapy in Liver Diseases: The Pathophysiological Basis of Therapy* 1997:335-47.

17. *Smedile A, Wands JR. Hepatitis B: basic science and epidemiology/Hepatitis D. In: Rizzetto M, Purcell RH, Gerin JL, Verme G (eds). Viral Hepatitis and Liver Diseases 1997:906-10.*

## MANUSCRIPTS SUBMITTED OR IN PREPARATION

1. *Merle P, Herrmann M, Lefrancois L, Califano S, Tanaka S, Trepo C, Vitvitski L, de la Monte S, Wands JR.* Oncogenic role and specific expression of the frizzled family receptors in different transgenic murine models of hepatocellular carcinoma. *J Clin Invest* (submitted).
2. *Lahousse SA, Carter JJ, Doiron K, Manley P, Xu JX, Wands JR, de la Monte SM.* Growth factor regulation of aspartyl-(asparaginyl)- $\beta$ -hydroxylase expression and functional relationship to motility in human neuroblastoma cells. *Mol Cell Bio* (submitted).
3. *Gehring S, Gregory SH, Kuzushita N, Wands JR.* Immune modulatory effects of type 1 interferon on DNA-based vaccination against hepatitis C virus core protein. *J Immunol* (submitted).
4. *Gehring S, Gregory SH, Kuzushita N, Wands JR.* Type 1 interferon augments DNA-based vaccination against hepatitis c virus core protein. *Gastroenterology* (submitted).
5. *Yoon SK, Lim NK, Ha S, Park YG, Choi JY, Chung KW, Sun HS, Choi MJ, Chung J, Wands JR, Kim JW.* The HCCR protein is a biomarker for human hepatocellular carcinoma. *Cancer Research* (submitted).
6. *Aloman C, Kuzushita N, Gehring S, Wands JR.* Ethanol alters dendritic cell function in vivo and impairs the subsequent cellular immune responses to hepatitic C viral proteins. *Alcoholism: Clinical and Experimental Research* (in press).
7. *Derdak Z, Fulop P, Sabo E, Konkin T, Berthiaume E, Resnick M, Paragh G, Wands JR, Baffy G.* Enhanced colon tumor induction by azoxymethane in uncoupling protein-2 deficient mice is associated with NF- $\kappa$ B activation and oxidative stress. *Nature Medicine* (submitted).
8. *Lahousse SA, Wands JR, de la Monte SM.* Cyclin dependent kinase 5 regulates aspartyl (asparaginyl)-beta-hydroxylase expression and function in neuroblastoma cells. *J Neuroscience* 2006 (submitted).
9. *Gholam P, Taylor L, Delong AK, Gardner L, Klein RS, Cintron V, Wu Z, Rompalo A, Schuman P, Lazarus T, Carpenter C, Wands JR.* Occult hepatitis B and seronegative hepatitis C viremia in women with and at risk for HIV infection. *N Engl J Med* (Submitted).
10. *Hong J, Behar J, Wands JR, Resnick M, Wang LJ, DeLellis RA, Lambeth D, Cao W.* Bile acid receptor TGR5-mediated NADPH oxidase NOX5-S expression contributes to

taurodeoxycholic acid induced increase in cell proliferation in Barrett's esophageal adenocarcinoma cells. *Mol Cell Biol* (submitted)

11. Qin Y, Zhang J, Garcia T, Ito K, Gutelius D, Wands J, Li J, Tong S. Circularized genome from monomeric constructs and clone pools to study HBV virus replication and protein expression. *Virus Research* (submitted)
12. Eken A, Wands JR. Hepatitis C virus, alcohol and dendritic cell dysfunction. Diamond I, HoeK J (Ed). *ACER* i.e. mini review from NIH NIAAA RSA symposium on Alcohol and HCV (in press)
13. Li JS, Wands JR. Initiation of duck hepatitis B virus infection requires cleavage by a furin-like protease. *J Virol* (in press).
14. Setshedi M, Longato L, Petersen D, Ronis M, Wands JR, de la Monte SM. Additive impact of ethanol on chronic high fat intake in promoting steatohepatitis and hepatic insulin resistance: effects of N-acetylcysteine. *Am J Physiology* 2012 (submitted)

## ABSTRACTS (1994-2011)

1. *Wakita T, Tokushige K, Moradpour D, Wands JR.* Dual effects of antisense oligonucleotide on hepatitis C virus antigen expression. *Hepatology* 1994;20:171A.
2. *Iwata K, Wakita T, Okumura A, Yoshioka K, Takayanagi M, Wands JR, Kakumu S.* IFN- $\gamma$  production by peripheral blood lymphocytes to hepatitis C virus core protein and definition of immunodominant epitopes in chronic hepatitis C. *Hepatology* 1994;20:204A.
3. *Moradpour D, Wakita T, Tokushige K, Wands JR.* Three novel monoclonal antibodies specific for the hepatitis C virus core protein. *Hepatology* 1994;20:230A.
4. *Tokushige K, Pachuk C, Wakita T, Moradpour D, Wang B, Boyer J, Coney L, Weiner DB, Wands JR.* Development and immune response to HCV core DNA vaccine constructs. *Hepatology* 1994;20:230A.
5. *Scaglioni PP, Melegari M, Wands JR.* Characterization of hepatitis B virus core mutants that inhibit viral replication. *Hepatology* 1994;20:264A.
6. *Ito T, Tanaka S, Wands JR.* Overexpression of the human insulin receptor substrate-1 (hIRS-1) gene induces cellular transformation through mitogen-activated protein kinases (MAPKs). *Hepatology* 1994;20:273A.
7. *Bhavani K, Chisari FV, Ito T, Wands JR.* Increased tyrosyl phosphorylation of insulin receptor substrate-1 in HCC tumors derived from HBV surface antigen transgenic mice. *Hepatology* 1994;20:273A.
8. *Lavaissiere L, Wands JR, Takahashi H.* Molecular characterization and cloning of FB-50 antigen highly expressed in human hepatocellular carcinoma. *Hepatology* 1994;20:275A.
9. *Moradpour D, Compagnon B, Nicolau C, Wands JR.* Specific targeting of human hepatocellular carcinoma cells by immunoliposomes *in vitro*. *Hepatology* 1994;20:277A.
10. *Fujimoto J, Hanada S, Wands JR, Takahashi H.* Acute hepatitis and viral clearance in rats expressing human hepatitis B virus transgenes. *Hepatology* 1994;20:277A.
11. *Wakita T, Tokushige K, Moradpour D, Liang TJ, Hayashi N, Kakumu S, Muto Y, Wands JR, Takahashi H.* Antigenic alteration of hepatitis B virus core protein in fulminant hepatitis. *Hepatology* 1994;20:295A.
12. *Tong S-P, Li JS, Wands JR.* Characterization of a hepatocyte membrane glycoprotein that specifically binds to the pre-S region of the duck hepatitis B virus. *Hepatology* 1994;20:303A.

13. *Melegari M, Wands JR*. Functional characterization of HBV spliced transcripts derived from patients with chronic HBV infection. *Hepatology* 1994;20:304A.
14. *Scaglioni PP, Melegari M, Takahashi M, Chowdhury R, Wands JR*. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. *Hepatology* 1995;22:224A.
15. *Wakita T, Moradpour D, Tokushige K, Wands JR*: Specific inhibition of hepatitis C virus core antigen production by antisense RNA constructs. *Hepatology* 1995;22:330A.
16. *Moradpour D, Wakita T, Englert C, Wands JR*: Specific inhibition of hepatitis C virus gene expression by antisense oligonucleotides in a tightly regulated cell culture system. *Hepatology* 1995;22:330A.
17. *Melegari M, Scaglioni PP, Wands JR*: Characterization of a liver specific HBx interacting protein XIP. *Hepatology* 1995;22:262A.
18. *Geissler M, Tokushige K, Wands JR*: Polynucleotide based immunization: study of the humoral and the cellular immune response to hepatitis B. *Hepatology* 1995;22:324A.
19. *Li J-S, Tong S-P, Wands JR*: A binding protein for carboxyl terminal dibasic amino acid residues of truncated duck hepatitis B virus pre-S protein. *Hepatology* 1995;22:269A.
20. *Ito T, Tanaka S, Wands JR*: Role of signal transduction pathways in hepatic transformation induced by overexpression of the human insulin receptor substrate-1 (IRS-1). *Hepatology* 1995;22:199A.
21. *Tong S-P, Li J-S, Wands JR*: Interaction between a carboxypeptidase-like protein and neutralizing epitopes of duck hepatitis B virus pre-S protein. *Hepatology* 1995;22:269A.
22. *Tanaka S, Ito T, Wands JR*: Cellular transformation induced by insulin receptor substrate-1 overexpression requires an interaction with both Grb2 and Syp signal transduction molecules. *Hepatology* 1995;22:234A.
23. *Tokushige K, Wakita T, Moradpour D, Wands JR*: Expression and immune response to hepatitis C virus DNA vaccine constructs. *Hepatology* 1995;22:220A.
24. *Tanaka S, Wands JR*: Reversal of the human hepatocellular carcinoma malignant phenotype. *Hepatology* 1996;24:248A.
25. *Tanaka S, Wands JR*: Insulin receptor substrate-1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor  $\beta$  1-induced apoptosis. *Hepatology* 1996;24:253A.

26. *Tanaka S, Schmidt EV, Mohr L, Sugimachi K, Wands JR: In vivo mitogenic effects of human insulin receptor substrate-1 (hIRS-1) overexpression in hepatocytes. Hepatology 1996;24:343A.*
27. *Compagnon B, Moradpour D, Alford DR, Larsen CE, Stevenson MJ, Mohr L, Wands JR, Nicolau C: Enhanced gene delivery and expression in human hepatocellular carcinoma cells by cationic immunoliposomes. Hepatology 1996;24:464A.*
28. *Scaglioni PP, Melegari MM, Yoon SK, Wands JR: Post-transcriptional regulation of HBV replication by the precore protein: potential use as a novel antiviral agent. Hepatology 1996;24:222A.*
29. *Melegari MM, Scaglioni PP, Wands JR: Molecular properties of pre-S1 deleted HBV genomes found during chronic HBV infection. Hepatology 1996;24:408A.*
30. *Melegari MM, Scaglioni PP, Wands JR: Molecular identification and characterization of XIP as a hepatitis B x protein (HBx) interactor that downregulates HBV replication. Hepatology 1996;24:408A.*
31. *zu Putlitz J, Wieland S, Blum HE, Wands JR: Detection and characterization of antisense and sense RNA species that inhibit hepatitis B virus replication. Hepatology 1996;24:408A.*
32. *zu Putlitz J, Schroder CH, Zentgraf HW, Wands JR: Cloning, bacterial expression and characterization of immunoglobulin variable regions from a murine monoclonal antibody directed against hepatitis B virus x protein. Hepatology 1996;24:409A.*
33. *Li J-S, Tong S-P, Wakita T, Wands JR: A binding partner for duck hepatitis B virus pre-S protein with selective expression in viral infectible tissues. Hepatology 1996;24:222A.*
34. *Geissler M, Tokushige K, Wakita T, Wands JR: Immunological characterization of HCV-core/HBV-envelope chimeric constructs using genetic immunization. Hepatology 1996;24:262A.*
35. *Geissler M, Gesien A, Tokushige K, Wands JR: Enhancement of cellular and humoral immune responses to hepatitis C virus (HCV) core protein using DNA based vaccines augmented with cytokine expression plasmids. Hepatology 1996;24:357A.*
36. *Ito T, Sasaki Y, Wands JR, Hayashi N: Oncogenic signal transduction pathways through insulin receptor substrate-1 (IRS-1), Shc, and Grb2 in human hepatocellular carcinomas (HCC). Hepatology 1996;24:364A.*
37. *Heintges T, Encke J, zu Putlitz J, Wands JR: Assembly of a cDNA encoding the entire genome of hepatitis C virus. Hepatology 1997;26:298A.*



38. *Encke J, zu Putlitz J, Heintges T, Wands JR*: Total chemical synthesis with oligodeoxynucleotides of the 3' untranslated region of hepatitis C virus. *Hepatology* 1997;26:209A.
39. *Encke J, Geissler M, zu Putlitz J, Wands JR*: Genetic immunization generates broad based cellular immune responses against the nonstructural proteins of hepatitis C virus. *Hepatology* 1997;26:412A.
40. *Geissler M, Gesien A, Wands JR*: The inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus (HCV) core protein is reversed by genetic immunizations augmented with cytokine expressing plasmids. *Hepatology* 1997;26:412A.
41. *Geissler M, Blum HE, Wands JR*: Differential cellular and humoral immune responses to hepatitis B virus large and middle envelope proteins after genetic immunizations augmented with IL-2 and GM-CSF expressing plasmids. *Hepatology* 1997;26:224A.
42. *Geissler M, Bruss V, Blum HE, Wands JR*: Influence of hepatitis B virus envelope antigen secretion and retention of cellular and humoral immune responses in the context of genetic immunization. *Hepatology* 1997;26:223A.
43. *Geissler M, Gesien A, Wands JR*: Chronic ethanol effects on cellular immune responses to hepatitis B virus envelope protein: an immunologic mechanism for induction of persistent viral infection in alcoholics. *Hepatology* 1997;26:224A.
44. *zu Putlitz J, Wands JR*: Cloning, bacterial expression and characterization of immunoglobulin variable regions from a murine monoclonal antibody directed against hepatitis B virus surface protein. *Hepatology* 1997;26:426A.
45. *zu Putlitz J, Wands JR*: A novel deletion mutant of hepatitis B virus detected in a patient with chronic hepatitis. *Hepatology* 1997;26:220A.
46. *Tong J, Li J-S, Wands JR*: P170 is a cell surface binding receptor for duck hepatitis B virus. *Hepatology* 1997;26:224A.
47. *Melegari M, Scaglioni PP, Wands JR*: Biological properties of hepatitis B viral genomes with mutation in the precore promoter and ORF. *Hepatology* 1997;26:219A.
48. *Melegari M, Scaglioni PP, Wands JR*: Hepatitis B virus mutants induced by 3 TC and famciclovir are replication defective. *Hepatology* 1997;26:368A.
49. *Mohr L, Schauer I, Boutin RH, Moradpour D, Wands JR*: Targeted gene delivery to hepatocellular carcinoma cells using a monoclonal antibody based nonviral gene delivery system. *Hepatology* 1997;26:364A.

50. *Mohn S, Tanaka S, Wands JR*: Chronic ethanol feeding inhibits hepatocyte proliferation via the insulin receptor substrate-1 (h-IRS-1) signal transduction cascade in transgenic mice. *Hepatology* 1997;26:363A.
51. *Heintges T, zu Putlitz J, Wands JR*: Cloning, recombinant expression, characterization and sequencing of monoclonal antibodies against hepatitis C virus core protein. *Hepatology* 1997;26:258A.
52. *de la Monte SM, Ganju N, Tanaka S, Brown NV, Wands JR*: Ethanol-inhibition of insulin-stimulated GAPDH expression is mediated through specific motifs of insulin receptor substrate-1. *Hepatology* 1997;26:373A.
53. *Ito T, Sasaki K, Horimoto M, Hayashi N, Hori M, Wands JR*: Acquisition of resistance to apoptosis by insulin receptor substrate-1 (IRS-1) overexpression. *Hepatology* 1997;26:255A.
54. *Mohr L, Yoon S-K, Eastman SJ, Scheule RK, Chu Q, Scaglioni PP, Heintges T, Wands JR*: *In vivo* gene delivery to the liver and to intrahepatic tumors with cationic liposomes in nude mice. *Hepatology* 1997;26:363A.
55. *Yoon SK, Scaglioni PP, Mohr L, Melegari M, Armentano D, de la Monte SM, Wands JR*: Adenovirus mediated gene transfer and expression in mouse liver. *Hepatology* 1997;26:633A.
56. *Ince N, de la Monte SM, Jia S, Friedman P, Wands JR*: Overexpression of HAAH (human aspartyl, asparaginyl hydroxylase) in bile ducts is related to malignant transformation. *Hepatology* 1997;26:362A.
57. *Mohr L, Tanaka S, de la Monte SM, Wands JR*: Proliferative response of hepatocytes to human insulin receptor substrate-1 (h-IRS-1) overexpression in the liver of transgenic mice. *Hepatology* 1997;26:372A.
58. *Heintges T, Encke J, zu Putlitz J, Wands JR*: Characterization of antisense oligodeoxynucleotides (ODN) and proteinase inhibitors that inhibit hepatitis C virus NS3 function. 1998;28:286A.
59. *Heintges T, zu Putlitz J, Wands JR*: Cloning, bacterial expression and sequencing of human antibody fragments against hepatitis C virus NS3 by phage display of a combinatorial phagemid library. *Hepatology* 1998;28:287A.
60. *Encke J, Wands JW*: Chronic ethanol consumption inhibits immune responses against hepatitis C virus nonstructural NS5 protein. *Hepatology* 1998;28:304A.
61. *Tong S, Li J, Wands JR*: Carboxypeptidase D serves as a hepatitis B virus receptor following reconstitution of non-permissive cell lines. *Hepatology* 1998;28:395A.

62. *Ince N, Wands JR*: The aspartyl (asparaginy)  $\beta$  hydroxylase gene found overexpressed in human cholangiocarcinomas induces malignant transformation *Hepatology* 1998;28:415A.
63. *Ito T, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Toyama T, Hayashi N, Hori M, Wands JW*: Promotion of hepatocarcinogenesis through utilization of RAS by insulin receptor substrate-1 (IRS-1) overexpression. *Hepatology* 1998;28:416A.
64. *Encke J, zu Putlitz J, Geissler M, Wands JR*: Genetic immunization against the nonstructural proteins NS3, NS4 and NS5 of hepatitis C virus generates broad based cellular and humoral immune responses and protection in a tumor model. *Hepatology* 1998;28:465A.
65. *Encke J, Geissler M, de la Monte SM, Schmidt EV, Wands JR*: Genetic immunization breaks tolerance in hepatitis C virus (HCV) core transgenic mice. *Hepatology* 1998;28:466A.
66. *Encke J, zu Putlitz J, Wands JR*: Immunostimulatory CpG motifs enhance antibody production but not cellular immune responses *in vivo* after genetic immunization. *Hepatology* 1998;28:466A.
67. *Mohr L, Shankara S, Roberts B, Armentano D, Wands JR*: Efficient tumor cell killing and pronounced bystander effect by adenovirus mediated transfer of the E. coli purine nucleoside phosphorylase gene to hepatocellular carcinoma cells. *Hepatology* 1998;28:504A.
68. *zu Putlitz J, Yu O, Burke JM, Wands JR*: *In vitro* selected hairpin ribozymes inhibit hepatitis B virus replication in human hepatoma cells. *Hepatology* 1998;28:517A.
69. *Yoon SK, de la Monte SM, Armentano D, Wands JR*: CD95 (APO-1/FAS) and P53 mediated apoptosis associated with experimental adenoviral hepatitis. *Hepatology* 1998;28:518A.
70. *Yoon SK, Mohr L, Armentano D, Wands JR*: Adenovirus-mediated gene transfer to hepatocellular carcinoma in nude mice. *Hepatology* 1998;28:518A.
71. *Yoon SK, Mohr L, O'Riordan C, Armentano D, Wands JR*: Targeting of recombinant adenovirus to hepatocellular carcinoma cells using a tumor specific bifunctional Fab complex. *Hepatology* 1998;28:518A.
72. *Mohr L, Rainov N, Mohr U, Breakefield XO, Wands JR*: The use of rabbit cytochrome P450 4B1 as new prodrug activator for gene therapy of hepatocellular carcinoma. *Hepatology* 1998;28:518A.

73. *zu Putlitz J, Lanford RE, Carlson RI, Notvall L, de la Monte SM, Wands JR*: Properties of hepatitis B virus polymerase revealed by monoclonal antibodies. *Hepatology* 1998;28:580A.
74. *Melegari M, Scaglioni PP, Wands JR*: HBx acts as a weak transactivator when expressed by HBV replication competent genomes. *Hepatology* 1998;28:581A.
75. *zu Putlitz J, Encke J, Wands JR*: DNA-based immunization generates cellular immune responses against hepatitis B virus polymerase. *Hepatology* 1998;28:581A.
76. *zu Putlitz J, Skerra A, Wands JR*: An intracellular antibody fragment inhibits hepatitis B virus surface antigen secretion. *Hepatology* 1998;28:590A.
77. *Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR*: Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. *Hepatology* 1998;28:602A.
78. *Encke J, zu Putlitz J, Carlson RI, Wands JR*: Monoclonal antibodies generated against HCV nonstructural NS4 protein by a combination of protein and DNA-based immunization. *Hepatology* 1998;28:681A.
79. *Encke J, zu Putlitz J, Carlson RI, Wands JR*: Development, characterization, and mapping of monoclonal antibodies against hepatitis C virus nonstructural protein 3. *Hepatology* 1998;28:681A.
80. *Ito T, Sasaki Y, Yoshihara H, Masuda E, Suzuki K, Hori M, Kanada T, Hayashi N, Wands JR*: Human hepatocellular carcinoma cell resistance to apoptosis induced by insulin receptor substrate-1 (IRS-1); overexpression is mediated by suppression of stress-activated protein kinase (SAPK) activity. *Hepatology* 1999;30:390A.
81. *Li J, Tong S, Wands JR*: The differentiation status of primary duck hepatocytes is critical for duck hepatitis B virus replication but not for virus binding or entry. *Hepatology* 1999;30:404A.
82. *Tong S, Li J, Spangenberg HC, Wands JR*: Characterization of duck carboxypeptidase D as a duck hepatitis B virus receptor. *Hepatology* 1999;30:402A.
83. *Tamaki S, Ince N, de la Monte SM, Mohr L, Wands JR*: Overexpression of the aspartyl-asparaginyl  $\beta$ -hydroxylase (AAH) in livers of hIRS-1 transgenic mice. *Hepatology* 1999;30:401A.
84. *Wiedmann M, Wands JR, Mao Z*: Characterization of myocyte enhancer factor 2 (MEF2) expression and functional analysis during hepatocyte growth and differentiation. *Hepatology* 1999;30:1999;30:513A.

85. *Ince N, Hasan S, Tanaka S, Wands JR:* The insulin receptor substrate-1 (hIRS-1) signal transduction pathway influences expression of human aspartyl (asparaginyl) beta-hydroxylase (HAAH) in human hepatocellular carcinoma cells. *Hepatology* 1999;30:510A.
86. *Hasan S, Wands JR:* Role of IL-6 and EGF in inhibiting bleomycin-induced P53 activation in HepG2 cells. *Hepatology* 1999;30:405A.
87. *Li JS, Tong S, Wands JR:* Identification of glycine decarboxylase (p120) as a duck hepatitis B virus pre-S envelope binding protein: association with cell differentiation status and virus replication. *Hepatology* 1999;30:404A.
88. *Heintges T, zu Putlitz J, Wands JR:* Characterization and binding of intracellular antibody fragments to the hepatitis C virus core protein. *Hepatology* 1999;30:353A.
89. *Fukutomi T, de la Monte SM, Tamaki S, Maeda T, O’Riordan C and Wands JR:* Targeted adenoviral vector-mediated gene transfer to hepatocellular carcinoma cells using AF-20 monoclonal antibodies. *Hepatology* 2000;79:182A.
90. *Wiedmann M, Tamaki S, de la Monte SM, Cousens L and Wands JR:* Increased FAS receptor expression and function limits liver growth in a transgenic mouse model of constitutive hepatocyte proliferation. *Hepatology* 2000;192:209A.
91. *Tamaki S, de la Monte SM, Ince N, Torimura T, Ueno T and Wands JR:* Chronic alcohol consumption inhibits the CTL response against hepatitis C virus (HCV) NS5 protein following DNA based immunization in a syngeneic tumor model. *Hepatology* 2000;245:222A.
92. *Tamaki S, de la Monte SM, Ince N, Wands JR:* Over-expression of the aspartyl (asparaginyl) beta hydroxylase gene enhances invasive growth of hepatocellular carcinoma cells. *Hepatology* 2000;650:322A.
93. *Ince N, Demir K, Wands JR:* Association of human aspartyl (asparaginyl) betahydroxylase (HAAH) with NOTCH and NOTCH-ligand expression during hepatocarcinogenesis. *Hepatology* 2000;654:323A.
94. *Khamzina L, Gruppuso P, Wands JR:* Insulin-receptor-substrate-1, 2, 3 and 4 during normal rat liver development: their expression and relation to hepatic growth. *Hepatology* 2000; 668:326A.
95. *Lee HB, Tong SP, Spangenberg HC, Wands JR, Li JS:* Expression patterns of DHBV receptor/co-receptor proteins in viral susceptible vs. non-susceptible hepatocytes. *Hepatology* 2000; 881:380A.
96. *Tong SP, Li JS, Spangenberg HC, Lee HB, Parekh S, Wands JR:* Characterization of the early events of duck hepatitis B virus (DHBV) life cycle through reconstitution with duck carboxypeptidase D (p170) and duck glycine decarboxylase (p120). *Hepatology* 2000;932:392A.

97. *Li JS, Tong SP, Spangenberg HC, Lee HB, Wands JR*: Duck hepatitis B virus infection of primary mouse hepatocytes reconstituted with virus receptor/co-receptors. *Hepatology* 2000; 1143:445A.
98. *Spangenberg HC, Lee HB, Li JS, Wands JR, Tong SP*: A small region in the duck carboxypeptidase D receptor is essential for duck hepatitis B virus binding and internalization. *Hepatology* 2000;1152:447A.
99. *Parekh S, Zoulin F, Li JS, Treppe C, Wands JR, Tong SP*: Enhanced replication capacity of naturally occurring HBV variants is associated with sequence variation in the core promoter region. *Hepatology* 2000;1154:448A.
100. *Li JS, Tong SP, Lee HB, Spangenberg HC, Wands JR*: Expression of duck glycine decarboxylase (p120) is necessary for cccDNA formation and entry into the life cycle of duck hepatitis B virus replication. *Hepatology* 2000;1170:452A.
101. *Maeda T, Sepe P, Lahousse S, Tamaki S, Wands JR, de la Monte S*: Antisense oligonucleotide of human aspartyl (asparaginyl)  $\beta$ -hydroxylase suppresses migration of human cholangiocellular carcinoma cells. *Hepatology* 2001; 34:267A.
102. *Lee HB, Li JS, Spangenberg HC, Wands JR, Tong S*: Identification of a 65-kDa duck serum protein as a binding partner for carboxypeptidase D, the duck hepatitis B virus receptor. *Hepatology* 2001; 34:306A.
103. *Spangenberg HC, Lee HB, Li JS, Tang F, Skidgel R, Wands JR, Tong S*: Duck hepatitis B virus interacts with duck but not human carboxypeptidase D: identification of the molecular basis for host specificity. *Hepatology* 2001; 34:307A.
104. *Tong S, Li SJ, Feldmann A, Spangenberg HC, Kawai S, Lee HB, Wands JR*: Evidence for the involvement of furin, a basic endopeptidase, in the DHBV life cycle. *Hepatology* 2001; 34:309A.
105. *Lee HB, Tong S, Spangenberg HC, Wands JR, Li JS*: Differential protein interaction patterns of glycine decarboxylase (p120) in duck hepatitis B virus susceptible vs. non-susceptible duck livers. *Hepatology* 2001; 34:309A.
106. *Silbermann R, Maeda T, Wiedmann M, Wands JR, de la Monte S*: In vivo gene transfer of HBx DNA results in increased hepatocyte turnover. *Hepatology* 2001; 34:383A.
107. *Wiedmann M, Wands JR, de la Monte S*: Constitutive over-expression of the insulin receptor substrate-1 causes functional up-regulation of Fas. *Hepatology* 2001; 34:247A.
108. *Dumoulin FL, Li JS, von dem Bussche A, Spengler U, Sauerbruch T, Wands JR*: Analysis of the impact of hepatitis C virus (HCV) NS2 protein on steady state mRNA levels in human hepatoma cells using cDNA array screens. *Hepatology* 2001; 34:388A.

109. *Maggio PM, Carlson RI, Wands JR*: Taurolidine treatment of hepatic metastases from colon cancer. *Hepatology* 2001; 34:389A.
110. *Li JS, Tong SP, Kawai S, Lee HB, Wands JR*: Further characterization of glycine decarboxylase (p120), a pre-S envelope-interacting protein in duck hepatitis B virus life cycle. *Hepatology* 2001; 34:312A.
111. *Khamzina L, Gruppuso PA, Wands JR*: Signaling by insulin receptor substrate 1 (IRS-1) during normal rat liver development and its relation to hepatic growth. *Hepatology* 2001; 34:385A.
112. *von dem Bussche A, Dumoulin FL, Merle P, Wands JR, Li J*. Regulation of viral and cellular gene transcription and hepatitis B virus replication by hepatitis C virus NS2 protein. *Hepatology* 2002;36:277A.
113. *Ahn SH, Kawai S, Spangenberg H, Parekh S, Li J, Wands JR, Tong S*. Naturally occurring mutations near precore translational initiation site reduce hepatitis Be antigen production. *Hepatology* 2002;36:370A.
114. *Yeon JE, Silbermann R, Wands JR, de la Monte SM*. In vivo gene delivery model for studying the function of the HBx gene in the liver. *Hepatology* 2002;36:440A.
115. *Li J, Tong S, Lee H, Zhou Y, Wands JR*. p120 glycine decarboxylase is a key component for establishing duck hepatitis B virus infection in primary duck hepatocytes. *Hepatology* 2002;36:366A.
116. *Lee HB, Spangenberg H, Li J, Wands JR, Tong S*. Identification of a 65-kDA duck serum protein as a binding partner for the soluble form of carboxypeptidase D, the duck hepatitis B virus receptor. *Hepatology* 2002;36:653A.
117. *Fukutomi T, Wands JR, Li J*. Hepatitis C virus core protein promotes cell proliferation and accelerates cell cycle progression. *Hepatology* 2002;36:207A.
118. *Kawai S, Tsai A, Zoulim F, Parekh S, Ahn SH, Khan N, Trepo C, Li J, Wands JR, Tong S*. Naturally occurring hepatitis B virus core promoter mutants with extremely high replication capacity. *Hepatology* 2002;36:367A.
119. *Tong S, Spangenberg H, Li J, Ahn SH, Kawai S, Wands JR*. Use of CoCl<sub>2</sub> to probe the unique property of carboxypeptidase D as a hepatitis B virus receptor. *Hepatology* 2002;36:621A.
120. *Tanaka S, Sugimachi K, Yamashita Y, Maehara S, Shirabe K, Shimada M, Wands JR*. Angiopoietin/Tie2 signaling in progression of hepatocellular carcinoma. *Hepatology* 2002;36:238A.
121. *Yoon SK, Kim SH, Song BJ, Cho S, Bae S, Choi JY, Lee YS, Chung KW, Wands JR*. Targeted cancer therapy using chimeric immunotoxin of AF-20 monoclonal antibody with pseudomonas exotoxin for hepatocellular carcinoma. *Hepatology* 2002;36: 389A.
122. *Fulop P, Wands JR, Baffy G*. UCP2 affects fasting-induced steatosis and metabolic parameters in lean and obese mice. *Hepatology* 2002;36:413A.

123. *Horimoto M, Fulop P, Derdak Z, Wands JR, Baffy G.* Uncoupling protein-2 deficiency alters cell cycle protein expression in regenerating mouse Liver. *Hepatology* 2003;38:235A.
124. *von dem Bussche A, Wands JR, Li J.* Protein that mediates repression of cellular and viral gene transcriptional activity. *Hepatology* 2003;38:356A.
125. *Wang X, Tang X, Gong X, Wands JR, Friedman S, Mao Z.* MEF2 regulates hepatic stellate cell activation and growth. *Hepatology* 2003;38:774A.
126. *Califano S, Yeon JE, Xu J, Wands JR, de la Monte SM.* Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. *Hepatology* 2003;.
127. *Bang G, Guarnieri M, Li J, Zhou Y, Wands JR, Tong S.* Natural occurring mutations affecting the intramolecular disulfide bond but not signal peptidase cleavage site greatly impair HbeAg formation. *Hepatology* 2003;38:611A.
129. *Khan N, Guarnieri M, Ahn S, Zhou Y, Li J, Wands JR, Tong S.* Identification of naturally occurring mutations in the S domain of hepatitis B virus envelope proteins that markedly enhance virion secretion. *Hepatology* 2003;38:609A.
130. *Gehring S, Kuzushita N, Gregory SH, Wands JR.* Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein. *Hepatology* 2003;38:634A.
131. *Kuzushita N, Gehring S, Gregory SH, Wands JR.* The use of NS5 protein-transduced dendritic cells as a novel approach for vaccination against hepatitis C virus. *Hepatology* 2003;38:185A.
132. *Kawai S, Fukutomi T, Wands JR, Li J.* Cellular proliferation and transcriptional changes induced by expression of hepatitis C virus core protein: implication for hepatic ontogenesis. *Hepatology* 2003;38:351A.
133. *Merle P, de la Monte S, Herrmann M, Tanaka S, Kew MC, Treppo C, Wands JR.* The role of Frizzled 7 expression in the pathogenesis of human hepatocellular carcinoma. *Hepatology* 2003;38:589A.
134. *Merle P, de la Monte S, Herrmann M, Tanaka S, Kim M, Trepo C, Wands JR.* Functional consequences of Frizzled-7 receptor over-expression in human hepatocellular carcinoma. *Hepatology* 2003;38:564A.
135. *Herrmann M, Merle P, de la Monte S, Lefrancois L, Califano S, Trepo C, Tanaka S, Wands JR.* Oncogenic role and specificity of Frizzled receptor expression in animal models of hepatocellular carcinoma. *Hepatology* 2003;38:180A.



136. *Tanaka S, Sugimachi K, Maehara S, Shirabe K, Shimada M, Wands JR, Maehara Y.* The Wnt-inducible signaling pathway 1 variant (WISP1v) is a novel oncogenic molecule that mediates invasion of cholangiocarcinoma cells. *Hepatology* 2003;38:
137. *Kim KH, Guarneri M, Tsai A, Wands JR, Tong S.* A short sequence in the 3' end of core gene is critical for hepatitis B virus genome replication, e antigen processing, and core protein nuclear localization. *Hepatology* 2004;40:592A.
138. *Kim KH, Ahn SH, Guarneri M, Wands JR.* Naturally occurring mutations in hepatitis B virus core gene modulate core protein and e antigen expression or their antigenicity. *Hepatology* 2004;40:595A.
139. *Kawai S, Fukutomi T, Zarnegar R, Li K, Zhou Y, Wands JR, Li SJ.* Transcriptional activation of hepatocyte growth factor by hepatitis C virus core protein. *Hepatology* 2004;40:441A.
140. *Aloman C, Yeung A, Gehring S, de la Monte SM, Wittrup D, Rosenblum M, Wands JR* Targeting hepatocellular carcinoma cells and tumors with high affinity single chain antibody fragment and intact AF20 antibody conjugated with methotrexate. *Hepatology* 2004;40:258A.
141. *Gehring S, Gregory SH, Aloman C, Kuzushita N, Wands JR.* Co-administration of non-primed dendritic cells strongly augments cellular and humoral immune responses to an hcv ns5 expressing plasmid. *Hepatology* 2004;40:251A.
142. *De la Monte SM, Tamaki S, Ince N, Wiedmann M, Carter J, Lahoussier S, Califano S, Maeda T, Ueno T, Wands JR.* Insulin receptor substrate-1 signaling pathways regulate aspartyl-(asparaginyl)- $\beta$ -hydroxylase expression: relevance to motility and invasive growth of hepatocellular carcinoma. *Hepatology* 2004;40:603A.
143. *Kuzushita N, Gregory SH, Monti N, Gehring S, Wands JR.* Protein-transduced dendritic cells as a novel approach for vaccination against hepatitis C virus infection. *Hepatology* 2003;40:313A.
144. *Berthiaume E, Derdak Z, Konkin T, Resnick M, Wands JR, Gyorgy B.* Increased expression of uncoupling protein-2 in cholangiocarcinoma cells may confer resistance to apoptosis. *Hepatology* 2004; 40:372A.
145. *Von dem Bussche A, Dumoulin FL, Wands JR, Li JS.* The hepatitis C virus ns2 protein activates ER stress signaling pathways: implications for viral pathogenesis. *Hepatology* 2004; 40:449A.
146. *Aloman C, Gehring S, Wands JR.* Ethanol alters dendritic cell function in vivo and impairs the subsequent cellular immune responses to hepatitis C. *Hepatology* 2005;42:568A.

147. *von dem Bussche A, Ke L, Zhou Y, Wands JR, Li J.* Characterization of cellular ER stress induced by hepatitis C virus NS2 protein in the context of HCV polyprotein expression and replication. *Hepatology* 2005;42:74A.
148. *von dem Bussche A, Fukutomi T, Kawai S, Wands JR, Li J.* Contribution of Wnt-1-WISP2 signaling in hepatocyte proliferation induced by hepatitis C virus core protein. *Hepatology* 2005;42:553A.
149. *Cantarini MC, de la Monte, SM, Trevisani F, Grigioni WF, Tong M, Wands JR.* Insulin-like growth factor (IGF) stimulation of HCC migration is mediated by divergent regulation of AAH and NOTCH signaling. *Hepatology* 2005;42:643A.
150. *Guarnieri M, Kim KH, Bang G, Zhou Y, Li J, Tang X, Wands JR, Tong S.* The G1862T mutation in the HBV genome impairs DNA replication at the step of core protein expression. *Hepatology* 2005;42:282A.
151. *Li K, fukutomi T, Kawai S, Zhou Y, Wands JR, Li J.* Transcriptional activation of apolipoprotein C-IV gene by hepatitis C virus core protein: implication for HCV related liver steatosis. *Hepatology* 2005;42:548A
152. *Gehring S, Gregory SH, Aloman C, Wintermeyer P, Wands JR.* Characterization of a novel approach for HCV immunization using splenic derived dendritic cells with phagocytosed HCV-NS5 coated magnetic beads. *Hepatology* 2005;42:540A.
153. *Wintermeyer P, Gehring S, Gregory SH, WandsJR.* Dendritic cell based immunization by targeting HCV-NS5 directly to dendritic cells in vivo using microbeads as vehicle. *Hepatology* 2006;44:237A.
154. *Derdak Z, Sheets A, Sabo E, Fulop P, Wands JR, Baffy G.* Fas-induced injury is diminished in UCP2-deficient ob/ob mice and points to cell-specific UCP2 expression in fatty liver. *Hepatology* 2006;44:214A.
155. *Sheets A, Derdak Z, Sabo E, Fulop P, Wands JR, Baffy G.* Fasting-induced changes in hepatic lipid metabolism are blunted in UCP2 deficiency and point to a novel physiological role. *Hepatology* 2006;44:482A.
156. *Gehring S, Gregory SH, Aloman C, Wintermeyer P, Wands JR.* Characterization of a novel approach for HCV immunization using splenic derived dendritic cells which phagocytosed HCV-NS5 coated magnetic beads. *Hepatology* 2006;44:312A.
157. *Kim E, Li K, Lieu C, Tong s, Zhou Y, Wands JR, Li J.* Transcriptional activation of apolipoprotein C-IV by hepatitis C virus core protein is mediated by Ku antigen/DNA dependent protein kinase complex. *Hepatology* 2006;44:303A.
158. *Kim KH, Tang X, Gewaily D, Li J, Wands JR, Tong S.* Opposing effects of two naturally occurring mutations in hepatitis B virus core protein on 2<sup>nd</sup> strand DNA synthesis. *Hepatology*

- 2006;44:538A.
159. *Toyama T, Lee HC, Wands JR, Kim M.* Wnt11 inhibits the canonical Wnt pathway through the activation of non-canonical signaling in human hepatocellular carcinoma cells. *Hepatology* 2006;44:593A.
  160. *Tsedensodnom O, Wands JR, Kim M.* Identification and characterization of transcription factor TCF-4 isoforms in human hepatocellular carcinoma. *Hepatology* 2006;44:593A.
  161. *Branda M, Longato L, Cantarini MC, Lee HC, Li J, Kim M, de la Monte SM, Wands JR.* Upregulation of Wnt and frizzled genes are biomarkers for hepatocellular carcinoma. *Hepatology* 2006;44:514A.
  162. *He J, de la Monte SM, Wands JR.* Acute effects of ethanol on insulin signaling. *Hepatology* 2006;44:430A.
  163. *Pang M, de la Monte SM, Cheng L, Tong M, Wands JR.* Inactivation of GSK-3 $\beta$  enhances expression of aspartyl (asparaginyl)- $\beta$ -hydroxylase and motility in hepatocellular carcinoma. *Hepatology* 2006;44:594A.
  164. *Gholam PM, Taylor LE, DeLong AK, Lazarus TS, Cintron V, Mayer KH, Klein RS, Schuman PC, Rompalo AM, Carpenter CCJ, Wands JR.* Occult HBV and HCV viremia in women at risk for and with HIV infection. *Hepatology* 2006;44:696A.
  165. *Laperle CM, Hamilton TJ, Cao G, Wintermeyer P, Diebold GJ, Rose-Petruck C, Wands JR.* High resolution x-ray phase contrast imaging and coupled computed tomography of excised murine liver samples.
  166. *Machida R, Heintges T, Tong S, Li J.* Intracellular targeting of hepatitis C virus core protein with a single chain antibody. *Hepatology* 2007;46:370A.
  167. *Kim A, Kawai S, Chung W, Kim E, Wands J, Li J.* Hepatitis C virus core protein selective activates cell growth factor signaling. *Hepatology* 2007;46:370A.
  166. *Machida R, Heintges T, Tong S, Li J.* Intracellular targeting of hepatitis C virus core protein with a single chain antibody. *Hepatology* 2007;46:370A.
  167. *Kim A, Kawai S, Chung W, Kim E, Wands J, Li J.* Hepatitis C virus core protein selective activates cell growth factor signaling. *Hepatology* 2007;46:434A.
  168. *Kim E, Wands J, Li J.* Apolipoprotein C-IV expression is regulated by Ku antigen and correlates with triglyceride accumulation in HCV infected liver. *Hepatology* 2007;46:435A.

169. Kwei K, Tang X, Konkin T, Li J, Wands J, Tong S. Hepatitis B virus vaccine escape mutants have impaired virion secretion efficiency in cell culture. *Hepatology* 2007;46:640A.
170. Longato L, de la Monte S, Kuzushita N, Horimoto M, Slagle B, Rogers A, Wands JR. Dual overexpression of insulin receptor substrate-1 and hepatitis Bx gene causes premalignant changes in liver. *Hepatology* 2007;46:272A.
171. Toyama T, Lee HC, Wands JR, Kim M. Wnt 1 inhibits the canonical Wnt pathway through the PKC-mediated  $\beta$ -catenin phosphorylation in human hepatoma cells. *Hepatology* 2007;46:775A.
172. Jiman H, de la Monte S, Wands JR. PTEN association with PI3K85 $\alpha$  subunit is a negative regulatory mechanism for insulin signaling in the liver. *Hepatology* 2007;45:776A.
173. Ito K, Guarnieri M, Garcia T, Li J, Wands JR. Naturally occurring mutations in the S domain of hepatitis B virus envelope proteins regulate virion secretion. *Hepatology* 2008;48:88A.
174. Tong Y, Machida R, Tong S, Wands JR, Li J. Cleavage of duck hepatitis B virus envelope protein by endosomal proprotein convertase promotes viral CCCDNA formation in non-susceptible LMH cells. *Hepatology* 2008;48:671A.
175. Machida R, Tong S, Heintges T, Wakita A, Wands JR, Li J. Interruption of hepatitis C virus particle formation by an intracellular antibody targeting the viral core protein. *Hepatology* 2008;48:759A.
176. Pang M, de la Monte S, He J, Chaudhry R, Duan K, Ouh J, Wands JR. Peroxisome proliferators activate receptor with agonist attenuates alcohol induced hepatic insulin resistance and improves liver injury and repair. *Hepatology* 2008;48:460A.
177. Toyama T, Lee HC, Wands JR, Kim M. Noncanonical Wnt11 signaling inhibits hepatocellular carcinoma cell proliferation and migration. *Hepatology* 2008;48:968A.
178. He J, de la Monte S, Wands JR. Regulation of insulin signaling in liver cells is mediated by an association of PI3K with N-terminal sequences of PTEN. *Hepatology* 2008;48:455A.
179. Garcia T, Li J, Sureau C, Wands JR, Tong S. Efficient hepatitis B virus secretion requires M protein expression but not overproduction of subviral particles. *Hepatology* 2009;50:985A.
180. Derdak Z, Wands JR. P53 enhances apoptosis and insulin resistance in the long-evans rat model of alcoholic liver disease (ALD) by activating novel downstream target genes. *Hepatology* 2009;50:1152A.

181. Shimoda M, Carlson R, Wands JR. Induction of antigen specific immunity against HCC with aspartate-b-hydroxylase and dendritic cell vaccine. *Hepatology* 2009; 50:1094A.
182. Tsedensodnom O, Koga H, Wands JR, Kim M. Identification of T-cell factor-4 splicing variants that influence the malignant characteristics of hepatocellular carcinoma. *Hepatology* 2009;50:628A.
183. Park J, Tong D, Kawai S, Wands JR, Li J. Comparison of growth factor/cancer signaling pathways in hepatoma derived Huh-7 vs. liver progenitor heparg cells. *Hepatology* 2009;50:949A.
184. Longato L, Tong M, Wands JR, de la Monte S. Ex vivo model of steatohepatitis using precision-cut liver slice cultures. *Hepatology* 2010;52:454A.
185. Koga H, Walker E, Tsedensodnom O, Nakashima O, Yano H, Wands JR, Kim M. A T-cell factor-4 isoform promotes an aggressive hepatocellular carcinoma phenotype involving hypoxia-inducible factor-2 $\alpha$ . *Hepatology* 2010;52:592A.
186. Feng D, Eken A, Wands JR. Ethanol feeding impairs dendritic cell (DC) function in the alcoholic liver disease (ALD) sensitive Long-Evans (LE) but not in resistant fisher rats. *Hepatology* 2010;52:613A.
187. Shimoda M, Carlson RI, Wands JR. Immunotherapy of hepatocellular carcinoma. *Hepatology* 2010;52:948A.
188. Derdak Z, Villegas KA, Wands JR. The p53 inhibitor, pifithrin-alpha p-nitro attenuates non-alcoholic fatty liver disease in mice. *Hepatology* 2010;52:1052A.
189. Setshedi M, Tong M, Feng D, Le T, Wands JR, de la Monte SM. Ceramide inhibitors and PPAR agonists ameliorate alcohol-induced steatohepatitis in an ex-vivo liver slice culture model. *Hepatology* 2010;52:1063A.
190. Derdak Z, Villegas KA, Wands JR. Fibrosis-related transcription factor early growth response-1 promotes steatosis in the liver of ethanol-fed long-evans rats by activating sterol regulatory element binding protein-1. *Hepatology* 2010;52:1112A.
190. Eken A, Wands JR. Ethanol inhibits presentation of allogeneic and exogenous antigens by dendritic cells. *Hepatology* 2010;52:1260A.
191. Zhou X, Li D, Resnick M, Behar J, Wands J, Wang LJ, DeLellis R, Cao W. NADH oxidase NOX5-S mediates acid-induced mPGES1 expression in Barrett's esophageal adenocarcinoma cells. *Gastroenterology* 2011;
192. Li D, Zhou X, Resnick M, Behar J, Wands J, Li JW, DeLellis R, Cao W. NADPH oxidase NOX5-S mediates acid induced DNA damage in Barrett's esophageal adenocarcinoma cells. *Gastroenterology* 2011;

193. Zhou X, Li D, Resnick M, Behar J, Wands J, Wang LJ, DeLellis R, Cao W. Signaling in H<sub>2</sub>O<sub>2</sub> induced increase in cell proliferation in Barrett's esophageal adenocarcinoma cells. *Gastroenterology* 2011;
194. Eken A, Ortiz V, Wands JR. Impairment of dendritic cell function by chronic ethanol consumption: unveiling its mechanism of action. *Hepatology* 2011;54:966A.
195. Chung W, Longato L, Kim M, de la Monte SM, Wands JR. Upregulation of aspartate  $\beta$ -hydroxylase (ASPH) is a key event in the pathogenesis of hepatocellular carcinoma (HCC). *Hepatology* 2011;54:1287A
196. Derdak Z, Villegas KA, Wands JR. Inhibition of p53 function diminishes steatosis in a mouse model of NAFLD. *Hepatology* 2011;54:388A.
197. Feng D, Eken A, Ortiz V, Wands JR. Chronic alcohol-induced liver disease role in the inhibition of dendritic cell function. *Hepatology* 2011;54:1109A.
198. Lizarazo D, Gao JS, Tong M, Wands JR, de la Monte SM. Indirect and direct roles of GSK-3 $\beta$  activation in relation to aspartyl-(asparaginyl)- $\beta$ -hydroxylase (AAH) expression and function: Consequences with respect to hepatocellular motility in ethanol-exposed cells. *Hepatology* 2011;54:969A.
199. Longato L, Ripp K, Setshedi M, Wands JR, de la Monte SM. Advanced human alcoholic liver disease is associated with increased pro-ceramide gene expression, ceramide accumulation, endoplasmic reticulum stress, and insulin/IGF resistance. *Hepatology* 2011;54:977A.
200. Setshedi M, Longato L, Ripp K, Chen WC, Nguyen QG, Wands JR, de la Monte SM. Triad of dysregulated signaling in human hepatocellular carcinomas (HCC) suggests multi-pronged approach is needed for therapeutic targeting. *Hepatology* 2011;54:1360A.
201. Noda T, Shimoda M, Sirica AE, Wands JR. Immunization with ASPH-loaded dendritic cells produces anti-tumor effects in a rat model of intrahepatic cholangiocarcinoma. *Hepatology* 2011;54:1281A.
202. Tsedensodnom O, Koga H, Wands JR, Kim M. Expression profile of fourteen splice-variants of T-Cell Factor-4 transcription factor of Wnt signaling in human HBV- and HCV-related HCC tissues. *Hepatology* 2011;54:1359A.